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Abstract 
Positron emission tomography (PET) imaging is a versatile modality with the ability to 
examine metabolic factors in individual tissues in vivo. It is an indispensable tool for 
research and treatment planning of diseases such as cancer. However, versatility could be 
increased if it were possible to image multiple tracers simultaneously. Such an ability could 
be important in developing a treatment strategy for diseases that remain intractable in the 
majority of cases, such as advanced glioma. 
Metabolic imaging with PET using target specific radiotracers has been shown to improve 
the delineation of tumour margins and provide increased information about tumour 
microbiology. However, the physical properties of radiotracers limits their combined use, 
such that imaging of more than one molecular target using PET is not generally considered 
feasible. 
Multiplexing PET imaging (dual-tracer PET) offers a solution that allows for individual PET 
imaging of two or more individual radiotracers, within the same scanning session. Although 
the technique was first proposed in the 1980s, this approach is not utilised despite offering 
significant advantages such as multiple target imaging and validation of new PET 
radiopharmaceuticals. Reasons for this lack of implementation may include assumptions 
about the potential loss in image quality and the logistics in synthesizing multiple PET 
tracers simultaneously.  
In this PhD, Dual-Tracer PET imaging techniques were developed, with a focus on the 
ability to validate chosen dual-tracer protocols prior to scanning. A set of techniques was 
devised to handle cases of increasing complexity: (initially) where the first tracer can be 
assumed to be static after a certain amount of time; secondly where the first tracer has a 
constant slow uptake that can be assumed to be linear; and the general case where the 
first tracer retains residual dynamics, with the use of a basis pursuit to separate the signals. 
These approaches were tested by applying them to specific, clinically relevant use cases. 
Development of these techniques has provided a framework for study designers to 
effectively implement dual-tracer PET imaging with confidence for the validation of new 
tracers, the investigation of cases where multiple biological factors are important and the 
further development of diagnosis and treatment in future applications. Finally, by utilising 
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basis pursuit approaches, it is possible to consider any combination of tracers regardless 
of tracer and without devising specific model of uptake within tissue.  
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Chapter 1 – Introduction 
Positron Emission Tomography (PET) has found increasing clinical use for the 
management of a range of diseases, including infiltrating advanced glioma, where it 
complements the information on oedema and blood brain barrier breakdown supplied by 
Magnetic Resonance Imaging (MRI) (1, 2). The utility of PET lies in its ability to identify 
regions with particular biological characteristics that are relevant to oncology management, 
which is accomplished through the use of radioactive tracers with specific molecular 
targets. With the development of novel therapeutics and more sophisticated treatment 
regimes, the need to image multiple molecular targets using PET imaging is becoming 
more apparent. This is the case for glioma, where the heterogeneous presence of hypoxic 
and metabolically active regions has potential relevance for planning surgery and 
radiotherapy. Metabolically active regions are likely to contain particularly aggressive 
phenotypes and hypoxic regions are known to be resistant to radiotherapy (3, 4). 
While multi-target PET imaging may provide additional important information, the physical 
properties of radiotracers limits their use, such that typical imaging of a second molecular 
target using PET while residual activity from the first tracer remains is not considered to be 
feasible. The longer the half-life of the first tracer, the longer the delay needed between the 
two scans. This is due to the fact that the PET scanner cannot differentiate between tracers 
for individual decay events. The current accepted method for acquiring information on more 
than one radiotracer is to perform multiple scans, with sufficient intervening time between 
the two scans to prevent cross-contamination. This process itself introduces a number of 
potential logistical and technical problems, including the introduction of image registration, 
a temporal gap in metabolic information, physiological changes due to patient 
movement/orientation, and an increase in scanner and specialist time. 
 
Research Rationale 
An alternative to performing multiple PET acquisitions is dual-tracer PET imaging, first 
proposed by Huang et al in 1982, where both radiotracers are imaged within a single 
scanning session and specific computational techniques are used to separate the signals 
of the two tracers post-reconstruction (5). Further investigations have sought to develop 
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dual-tracer imaging into a viable imaging tool. However, these methods are subject to 
certain limitations.  
Implementation of dual-tracer imaging potentially provides for the same benefits as two 
single scans, while circumventing some of the logistical issues imposed by separate 
scanning. In addition to providing more detailed information on intratumoral biology, the 
technique of dual-tracer imaging also lends itself to other applications, including novel 
tracer validation. With such a range of applications and clinical need, there is an inherent 
necessity for a set of tools that allow a study designer to investigate dual-tracer imaging, 
irrespective of the temporal characteristics of the tracers used and the variance in the 
pattern of tracer uptake within the field of view.  
To accomplish this, both static and dynamic reconstructions must be considered. Static 
reconstruction allows for a “snapshot” of the radiotracer activity to be taken over a short 
period of time. For dynamic imaging, acquisition begins from tracer injection, with computer 
post-processing (“kinetic modelling”) employed to analyse the temporal characteristics of 
the tracer.  
For dual tracer techniques, the following aspects are also to be taken into account: 
- Post-processing technique: The temporal behaviour of the tracers involved will 
determine the post-processing technique required to separate the two tracers. The 
more complex the residual dynamics of the first tracer at the injection of the second 
tracer, the more complex the post-processing technique will be required to separate 
the two tracer signals. 
- Imaging protocol: The length of the scan and the temporal gap between the injection 
of the two tracers will have an impact on the quality of the separated images. If the 
scanning length is too short, or the temporal gap is too small, the resulting tracer 
information will have increased error. In some cases, the increase in error will render 
the images unable to serve their intended purpose. 
Overall aims and outline of thesis 
Therefore, the overarching goal of this thesis is to design dual-tracer frameworks that can 
be applied to a wide variety of situations, and also allow the study designer to pre-validate 
the proposed protocol to ensure the efficacy of the resulting images. To accomplish this, 
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three frameworks for dual-tracer imaging are described and developed to cover the full 
range of scanning acquisitions and protocols. In this way, study designers can investigate 
potential dual-tracer imaging sequences against their selection of biology and radioactive 
tracer prior to performing any actual experiments. Hence, this thesis has three aims: 
1. Develop a framework to allow study designers to perform static dual-tracer imaging 
on a pair of tracers, where it can be assumed that the activity of the first tracer is at 
equilibrium. 
2. Extend this framework to consider the case where the first tracer has some residual 
dynamics. 
3. Develop a framework to allow dynamic dual-tracer imaging in the general case that 
can allow designers to consider any combination of tracers and tissue. 
These aims are investigated in the coming chapters, an outline of which is presented in 
Table 1-1. 
Table 1-1  Thesis overview 
Chapter Overview 
C
h
a
p
te
r 
2
 Background 
- Introduces PET imaging and glioma 
- Discusses the need for multi-tracer imaging 
- Introduces dual-tracer PET imaging and the current literature 
C
h
a
p
te
r 
3
 Dual acquisition of 18F-FMISO and 18F-FDOPA 
Presents a framework for static dual-tracer imaging where the activity of the 
first tracer is at equilibrium at injection of the second tracer (Thesis aim 1). 
Validated using 18F-FMISO and 18F-FDOPA.  
C
h
a
p
te
r 
4
 Extension to where first tracer dynamics are not at equilibrium 
Extends the previous chapter to include the ability to validate scanning 
protocols where the first tracer continues to have residual dynamics at the 
injection of the second tracer (Thesis aim 2). Validated using 64Cu-EphA2 
and 18F-FDOPA 
C
h
a
p
te
r 
5
 
Performing dual tracer PET imaging in the general case 
Develops a novel technique for validating protocols for performing dynamic 
dual-tracer PET imaging (Thesis aim 3). This technique employs a method 
called basis pursuit to fit the activity of the tracers over time, and 
subsequently separate them. This approach is validated using 18F-FDG and 
18F-FDOPA data. 
C
h
a
p
te
r 
6
 Summary 
- Summarises the contributions of the doctorate. 
- Discusses limitations of this work. 
- Discusses future research directions. 
  
4 
Chapter 2 – Background 
This chapter consists of two published papers: “Survey on utility and feasibility of 18F-
FDOPA in managing glioma” and “Hypoxia imaging in gliomas with 18F-
Fluoromisonidazole PET: Towards clinical translation”. Together, they analyse present 
suspected causes for treatment failure in glioma and the caveats of MR imaging. They 
systematically review and discuss the use of each tracer in the diagnosis and treatment of 
malignant glioma, demonstrating that these tracers could complement each other in clinical 
practice. Finally, the need for dual-tracer PET imaging is discussed, laying the foundation 
for the novel work in this doctoral thesis.  
Glioma 
Gliomas (Figure 2-1) are the most commonly occurring primary brain tumours, signified by 
their invasive potential and increased capacity for proliferation (2). These tumours have a 
uniformly poor prognosis, and while the median survival of patients with WHO grade IV 
gliomas (glioblastomas; GBM) is now longer than 12 months, most patients succumb within 
two years (6-8). Patient survival often depends largely on the extent of surgical resection, 
pretreatment functional status or the age of the patient (9-11). WHO Grade III anaplastic 
gliomas and WHO Grade II gliomas are less aggressive and have a more promising, yet 
still poor, prognosis of 2-5 and 2 years, respectively (12). Gliomas are the most common 
neoplasm in the brain, accounting for 80% of malignant brain tumours and 30% of all brain 
and CNS tumours (13, 14).  
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Figure 2-1Example brain slice of a patient with glioblastoma (WHO grade IV glioma). The patient was scanned with contrast 
enhanced MRI. The tumour is shown by the yellow arrow.  
Tumour recurrence plays a large role in patient mortality, with treatment resistance thought 
to take significant part in recurrence. A number of important factors are thought to promote 
resistance, including vasculogenesis, cancer stem cells (CSC), hypoxia, and infiltration, all 
of which are believed to be biologically linked within the tumour microenvironment. To 
understand their relevance to treatment outcome, in vivo imaging of glioma cases needs to 
be performed. PET imaging using tracers such as 18F-FMISO and 18F-FDOPA allow for 
characterisation of hypoxia and metabolism, respectively. Effective imaging of these 
tracers will help to describe the disease as well as assist in treatment planning regimes. 
Background to imaging with Positron emission tomography 
While current imaging techniques such as MRI are routinely used for oncological imaging, 
different imaging modalities have particular caveats. Positron emission tomography (PET) 
can provide information on the underlying microbiology of tumours such as glioma, 
complimenting structural information gained from MRI. PET imaging relies on the decay of 
a radioactive tracer injected into a patient to determine the location of a specific biological 
process. 
The first step in PET imaging is the synthesis of the radioactive tracer that will be injected 
into the patient, which is made up of two key components: the molecular analogue and the 
radioactive isotope. 
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The molecular analogue is first chosen as each analogue specifically targets a biological 
process. For example, 18F-FDG - the most common oncological tracer, is a glucose 
analogue and is taken up by cells during cell metabolism. 18F-FDG is transported into tumor 
cells and phosphorylated by hexokinase. Since 18F-FDG is not metabolised further, it 
remains metabolically trapped intracellularly as FDG-6-phosphate. Specifically, 18F-FDG is 
taken up by metabolising cells, but only excreted via the slower process of 
dephosphorylation which typically becomes apparent at 45 minutes post-injection, allowing 
for identificaton of particularly active cells (15). Since cancerous cells are more 
metabolically active than normal cells in most tissues, with the particular exception of 
tissues within the brain, uptake is more rapid, and thus a brighter spot on the PET image 
implies faster metabolism and is a sign of pathology. Analogues for other molecules also 
exist, which can be utilised to examine other aspects of disease. An outline of some of 
these analogues is shown in Table 2-1. 
 
Table 2-1 Common molecular analogues using in PET radiopharmaceuticals. 
Analogue Abbreviation Original 
molecule 
Target biological 
process 
Fluorodeoxyglucose FDG Glucose Metabolism 
fluoro-l-phenylalanine FDOPA L-Dopa Dopaminergic Activity 
Fluoromisonidazole FMISO Misonidazole Hypoxia 
Methionine MET Methionine Protein synthesis 
Fluorothymidine FLT Thymidine Proliferation 
Fluoro-ethyl-tyrosine FET Ethyl-tyrosine Infiltration 
 
There are a range of radioactive isotopes available, selection of which depends on isotope 
availability/synthesisability, half-life and ability to attach it to the molecular analogue. For 
PET imaging, only isotopes that decay by means of positron emission can be used. Table 
2-2 shows common radioactive isotopes used in PET imaging, along with their half-lives 
and synthesis method. A longer half-life is often desirable, as a half-life that is too short 
limits the use of the tracer to on-site scanners, or scanners within a short travelling time. 
However, a shorter half-life may be desired if the tracer is irreversibly bound in the tissue 
in order to limit radiation dose. 
Table 2-2  Radioactive isotopes commonly used in PET imaging, along with their half-lives and synthesis method. 
Isotope Name Half Life (Minutes) Synthesis method 
18F Fluorine 109.7 Cyclotron 
64Cu Copper 762.0 Cyclotron 
11C Carbon 20.33 Cyclotron 
15O Oxygen 2.037 Cyclotron 
68Ga Gallium 67.92 Generator 
82Ru Rubidium 1.273 Generator 
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Reconstruction of the acquired data can either be static or dynamic. Static imaging allows 
for a “snapshot” to be taken once an approximate equilibrium has been reached. Generally 
imaging is only over a few minutes (depending on specifics such as tracer half-life, rate of 
uptake and the injected activity), with the resulting image to be a sum or average of activity 
of the scan. This method is most commonly utilized in the clinic. Dynamic reconstruction 
can be from the injection of the radiotracer into the patient. After reconstruction, computer 
post-processing (“kinetic modelling”) is employed to analyse how the radiotracer behaves 
in the body over time. Dynamic imaging can provide additional salient information on the 
underlying tissue biology, and is more frequently used in the research setting. 
The processes involved in a typical clinical static PET scan are shown in Figure 2-2a for 
static imaging and Figure 2-2b for dynamic. 
 
Figure 2-2 Flowchart of typical static (a) and dynamic (b) PET scans. The stage at where the tracer is injected depends 
on the scanning type. For static scans, the tracer is injected prior to scanning to allow time for uptake of the tracer into 
the cells and near steady state to be reached. For dynamic scanning, the tracer is injected after scanning has been 
initiated so that full tracer pharmacokinetics can be acquired. 
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Once the scanning has been completed, the PET images are reconstructed into a 3D 
volume of interest (with a fourth temporal dimension where required) ready for post-
processing and analyses. Computed Tomography (CT) is often used to correct for 
attenuation due to denser tissue types. 
The synthesis and application of these tracers allows in vivo imaging of diseases such as 
glioma, and opens up new pathways for patient diagnosis and treatment. 
The role of 18F-FMISO and 18F-FDOPA in glioma 
18F-FMISO and hypoxia 
It has been shown that low oxygen tension is associated with persistent tumour activity 
following radiotherapy and the subsequent development of local recurrences and 
metastases (16-18). Cells become hypoxic when they exist at distances greater than 1-2 
mm from vasculature, where diffusion of oxygen is no longer possible (19). While hypoxia 
in normal tissue is rare, it is a known phenomenon found in most solid tumours and can be 
classified into three distinct types: chronic, acute and anaemic (20, 21). Chronic hypoxia 
was first hypothesized in 1955, when the central cores of bronchial tumours were noted to 
be necrotic (22). It occurs in cells that are no longer within range of vascularity, often due 
to the tumour outgrowing its blood supply or proliferation pressure forcing cells away from 
blood vessels. The presence of necrosis is a requirement in diagnosis of glioblastomas, as 
it signifies a high proliferation rate followed by outstripping of blood supply, resulting in 
chronic hypoxia and eventually necrosis (23). 
Acute hypoxic cells, in contrast, are cells temporarily oxygen deprived due to the brief 
closure of vessels. These closures are caused by severe vascular abnormalities within the 
tumour volume, leading to leaky vessels and alterations in intratumoral pressure. This can 
cause abrupt changes in blood supply, preventing oxygen and nutrients from reaching the 
tumour cells. Acutely hypoxic cells become normoxic again when blood flow is redirected 
back to the cells via angiogenesis or recanalisation of the vessels.  
Anaemic hypoxia relates to a reduced O2-carrying capacity of the blood supply. This may 
be associated with either the tumour or the treatment itself.  
It is well known that hypoxic tumour cells are more resistant to radiation, as the presence 
of oxygen facilitates the rendering of radiation induced DNA damage permanent. In fact, 2 
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to 3 times greater radiation dosage is required to induce cell death in hypoxic tissue 
compared with normoxic tissue (24). A recent study investigating the presence of persistent 
DNA double strand breaks (DSBs), which leads to mitotic cell death and tumour regression, 
has shed light on the association between hypoxia and radiation insensitivity (25, 26). In 
this study the dose-response of residual ΥH2AX foci, a robust measure of DSBs, was found 
to be highly dependent on tumour cell oxygenation, i.e. normoxic regions showed greater 
ΥH2AX expression indicating increased sensitivity to radiotherapy (27). 
Despite development of novel hypoxia targeting radiotracers, 18F-FMISO remains in use. 
Pioneering work by Valk et al some two decades ago, highlighted the role of 18F-FMISO as 
a hypoxic sensitizer in a small number of patients with high-grade gliomas (28). Initial 
uptake activity of 18F-FMISO at the site of blood-brain barrier BBB breakdown exceeded 
the activity in the normal cortex, with tumour hypoxia clearly delineable during the first five 
minutes of the 18F-FMISO scan. Uptake in tumoural regions exhibiting unperturbed BBB 
was slower, with maximum uptake peaking at around 40 minutes. In this early study, 
retention of 18F-FMISO occurred in two of the three patients, with uptake remaining 
significantly higher than cortical tissue. This work was the first to demonstrate using 18F-
FMISO PET that hypoxia does occur in human brain tumours, and suggested that 18F-
FMISO has potential for in vivo evaluation of hypoxia in glioma cases. 
18F-FDOPA and tumour infiltration 
For both newly diagnosed and recurrent brain tumours, it is imperative that the exact glioma 
tumour volume is known for both planning surgical resection and subsequent radiation 
therapy. The propensity for gliomas to infiltrate along white matter structures is well 
established from pathology studies (29, 30). It is also well known that lesions on an MRI do 
not necessarily correspond to regions of tumour infiltration (31). Thus, the use of MRI alone 
for surgical and radiotherapy planning runs the risk of underestimating the tumour volume. 
18F-FDOPA PET, on the other hand, has been shown to identify regions of infiltration and 
proliferation (32-39). 18F-FDOPA was first synthesised in the 1980’s for the purpose of 
examining Parkinson’s disease (40). However, a case study by Heiss et al in 1996 
illustrated a potential new role for 18F-FDOPA in the brain (41). While evaluating a 
movement disorder in a patient with suspected Parkinson’s disease, 18F-FDOPA imaging 
revealed a mass in the right frontal lobe. Further multi-modal studies investigating the lesion 
were suggestive of a low-grade glioma, with high 11C-MET uptake displayed within the 
same area. This unexpected, yet important finding was the first to describe the possibility 
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that 18F-FDOPA may provide complimentary information to other amino acid PET tracers, 
such as 11C-MET and 18F-tyrosine, in the assessment of gliomas.  
18F-FMISO, 18F-FDOPA and the link to MR imaging 
Contrast enhanced T1, T2 and FLAIR imaging are mainstays in the treatment planning and 
follow-up of patients diagnosed with gliomas (42, 43). There is evidence that a relationship 
between MR defined tumour volumes and hypoxia exists, as hypoxia is known to initiate 
the angiogenic cascade, resulting in eventual BBB breakdown: Hypoxia has been shown 
to promote neovascularization through a large number of molecular signals, leading to 
leakage of the blood-brain barrier (44, 45). A number of studies have been performed 
comparing the efficacy of 18F-FMISO PET and MRI in detecting regions of hypoxia.(46-49) 
Together, these results confirm a relationship between tumour hypoxia and MRI defined 
volumes and metabolic imaging, with 18F-FMISO PET appearing to provide an improved 
assessment of tumour hypoxia compared with surrogate MRI markers, such as contrast 
enhancement. 
In addition, current research studies suggest that a link between tumour infiltration as 
imaged by 18F-FDOPA and MRI derived indices exist (36, 50). Hence, while MRI is currently 
implemented in the diagnosis and treatment of glioma, studies support the potential of 18F-
FDOPA to provide information additional to that obtained from MRI (Figure 2-3). 
Specifically, 18F-FDOPA could provide further pathological information where MRI findings 
are negative in primary/recurrent tumours or inconclusive in recurrent tumours.  
 
  
11 
Figure 2-3 Figure 1 – a) Contrast enhanced MRI and b)18F-FDOPA imaging of a primary high-grade glioma (grade IV – 
GBM).  
 
Patient prognosis 
The ability to predict patient prognosis and response to therapy is of great importance. 
Currently, several factors such as Karnofsky performance status (an assessment tool for 
functional impairment; KPS), age, tumour size, extent of surgery, tumour grade and 
histology are used in predicting patient survival (51, 52). Previous studies have shown that 
18F -Fluorodeoxyglucose (18F-FDG) is also effective in predicting survival in primary and 
recurrent glioma patients (53, 54). However, the low specificity of 18F-FDG PET is a 
limitation. The idea that a link exists between hypoxia and patient life-span is not new and 
comes from the suspected link between radiation treatment, vasculogenesis, cancer stem 
cells (CSC), infiltration and hypoxia (24, 25, 55-57). As such, various prospective studies 
have been performed to evaluate the intratumoural partial pressure of oxygen (pO2) values 
on the outcome of tumour patients since the development of polarographic electrodes in 
the late 1980’s, with numerous studies specific to investigating 18F-FMISO PET and 
hypoxia (46, 47, 58-64). These studies provide evidence for a relationship between 
hypoxia, as measured by 18F-FMISO, and patient survival. This body of work is in 
agreement with a multitude of other cancer studies suggesting the relationship between 
hypoxia and prognosis exists (16, 17, 59, 65-70). 
A further study also suggests a link between 18F-FDOPA and patient prognosis, proposing 
that increased 18F-FDOPA uptake is predictive of reduced patient survival in cases of 
recurrent glioma (71). 
Glioma grading 
While anaplastic and mitotic activity exists in all grade gliomas, necrosis is not present in 
lower grade neoplasms due to the less aggressive conditions within the core (72-75). 
Confirmation of a GBM diagnosis generally involves surgical biopsy or resection, followed 
by a pathological assessment to determine tumour microvascularity, although there are 
concerns for this approach (9). Firstly, biopsy is an invasive procedure and is sometimes 
not possible due to the anatomic location of the tumour or the condition of the patient. 
Secondly, as biopsy tissue samples often represent only a small part of the entire tumour, 
there is a chance that the true tumour grade will be underestimated (76). Thirdly, surgery 
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of certain regions may involve surrounding normal brain tissue, exacerbating the prognosis 
by causing additional neurological morbidity or dysfunction (77).  
In contrast to biopsy and resection, current research suggests that the use of 18F-FMISO 
imaging may provide the ability to distinguish GBM from lower-grade gliomas in vivo (63, 
64, 78-80). Furthermore, there is some evidence that 18F-FDOPA can assist in tumour 
grading, though further research is needed before conclusions can be drawn confidently 
(33, 37, 81, 82). The ability to link glioma grade to non-invasive studies has clinical 
significance, even if employed only to aid guidance of tumour biopsy.  
From this body of research, it is clear that in vivo imaging of glioma using 18F-FMISO and 
18F-FDOPA PET is of importance, especially with the introduction of new hypofractionated 
stereotatic image-guided helical tomotherapy, where hypoxic tumoural regions can be 
treated with higher doses. Tomotherapy, as a salvage regime for recurrent high-grade 
gliomas, has shown promising results for improving patient survival (83). This suggests that 
the need to image more than one PET tracer is evident: Imaging with 18F-FMISO and 18F-
FDOPA PET provides valuable information not obtainable using either one individually. 
Although offering the potential to improve characterisation of tumour volumes, imaging 
multiple PET tracers is not often adopted due to technical and logistical constraints. As PET 
scanners cannot differentiate between individual tracer decay events, imaging more than 
one molecular target would require multiple PET acquisitions with a large enough temporal 
gap between them to prevent cross contamination. This approach not only increases 
scanner and specialist time, the poor health of patients may preclude multiple scans from 
being performed. Furthermore, higher grade gliomas are known to be fast progressing, 
suggesting that even a short temporal gap between independent scans may result in 
physiological changes in the tumour and underlying biology. Finally, individual acquisitions 
required registration, adding another source of potential uncertainty. 
Dual-Tracer PET imaging 
An alternative to performing multiple PET acquisitions is dual-tracer PET imaging, where 
both radiotracers are imaged within a single scanning session. Implementation of this 
technique could allow for information on multiple biological factors such as hypoxia and 
metabolism to be obtained within a single scanning session, potentially providing the same 
benefits as two single scans, while circumventing some of the logistical issues. Previous 
studies have suggested the potential of dual-tracer PET imaging. Huang proposed 
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exploiting the different decay rates of distinct isotopes to separate the signals once a 
biological steady state had been reached (5). Kadrmas et al implemented a novel method 
that combined distinct tracer half-lives with the biological kinetics of each tracer to separate 
18F-FDG, 64Cu-ATSM, 64Cu-PTSM and 11C-acetate signals (84). Here, PCA was used 
to examine mean signal separability as a function of injection delay and extract individual 
tracer signals; parameters were solved for a combined, pre-defined multi-compartment 
mode. Figueiras et al evaluated a simultaneous dual-tracer technique method that exploits 
the difference between the half-lives of 18F-FDG and 13N-ammonia in phantoms and an in 
vivo rat model of cerebral ischemia (85). Their model can be applied to the sinogram1 data 
or directly to reconstructed image data. Kadrmas et al performed an investigation using 
distinct tracer half-lives combined with biological kinetics to separate FDG, diacetyl-
bis(N(4)-methylthiosemicarbazone) (ATSM), pyruvaldehyde-bis(N4-
methylthiosemicarbazone) (PTSM) and acetate signals (84). In addition to exploiting the 
difference in tracer metabolic half-lives, Verhaeghe et al implemented a staggered injection 
interval between the two tracers in conjunction with a basis function separation method for 
the extraction of information from dual-tracer dynamic 18F-FDG and 15O-H2O acquisitions 
(86). Ikoma et al also relied on staggered injection intervals combined with kinetic modeling 
to assist in the separation of 18F-FDG and 11C-flumazenil (11C-FMZ) signals (87). Koeppe 
et al demonstrated that a gap between tracer injection allows three 11C-based tracers with 
the same isotope to be separated when using a two compartment kinetic model for each 
tracer (88). Kadrmas et al further investigated dual-tracer imaging by evaluating a kinetic 
model to separate 18F-FLT and 18F-FDG signals from dual-tracer simulations and in vivo 
studies of brain tumours (89). More recently, Zhang et al. proposed a method for separating 
two PET tracers using an extension of separable parameter space kinetic modelling to 
reduce the dimensionality of an otherwise complex non-linear fitting (90). 
Two studies have been performed investigating performing signal separation at the 
reconstruction level. Gao et al presented a technique where the kinetics of two tracers are 
used to constrain PET reconstruction (91). Cheng et al presented a novel method where a 
reduced-parameter dual-tracer kinetic model is incorporated into the reconstruction method 
to extract parametric maps (92).  
                                                 
1 The raw data collected during PET scanning is stored as a sinogram file, containing the count averages during each 
predefined time frame. 
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Finally, there has been some research into the field of triple coincidence PET imaging. 
Unlike the typical case, where double coincidences (a positron-electron annihilation event) 
are detected by the scanner, triple coincidence PET relies on detecting the additional 
gamma prompts that occur in the decay of some isotopes, and their inclusion in image 
reconstruction to enhance signal to noise ratio (93). With this in mind, separation of dual-
tracer signals could be performed using this third particle. However, the limitation with this 
approach is that triple coincidences are not guaranteed, and thus cross contamination of 
the signals is possible. In addition, the selection of tracers is limited to those where one 
(only) emits the third particle. 
These techniques establish dual-tracer PET imaging as a potential alternative to 
performing multiple PET acquisitions. Yet despite the potential utility of dual tracer 
techniques, they are not widely used, possibly because existing methods either:  
- Require each tracer to have a distinct half-life or radio-isotope, limiting the selection 
of available tracers. Each tracer has a specific half-life depending on the radio-
isotope attached to the tracer. These methods are inappropriate for 
hypoxia/infiltration imaging, as both 18F-FMISO and 18F-FDOPA are 18F radiotracers, 
and thus both have a half-life of 109 minutes.  
- Require the particular pharmacokinetic model to be specified to calculate 
parameters. Pre-defining a model can be a disadvantage when a model has not yet 
been developed for a new tracer, or where different models apply to different tissue 
regions within the field of view.  
Given these potential limitations, there is an inherent need to provide a set of dual-tracer 
frameworks to assist the study designer in selecting the most appropriate set of protocols 
for effectively performing dual-tracer imaging. In the following chapters, methods for 
performing dual-tracer imaging are presented that attempt to circumvent these limitations 
and move the current work in dual-tracer imaging towards clinical translation. 
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Chapter 3 – Dual acquisition of 18F-FMISO and 18F-
FDOPA 
Introduction 
Previous work demonstrates the potential of dual-tracer PET imaging for providing valuable 
metabolic information while circumventing some of the logistical issues of acquiring multiple 
PET scans. However, these methods are restricted to separating signals by either requiring 
that each tracer has a different half-life and exploiting the temporal difference, limiting the 
application to certain tracer combinations, or performing a full dynamic acquisition from the 
injection of the first tracer, significantly increasing the required scanner time. Given the 
potential value of combining information about tumour metabolism with hypoxia, this 
chapter considers the case of combining 18F-FMISO with 18F-FDOPA and consists of the 
published paper “Dual acquisition of 18F-FMISO and 18F-FDOPA”. Since 18F-FMISO uptake 
can be considered stable after the 2 to 4-hour post-injection interval typical of most studies, 
there exists the possibility of estimating the 18F-FMISO signal from a single frame prior to 
the injection of 18F-FDOPA, removing the need to scan from the injection of the first tracer 
(18F-FMISO).  
Recent work has suggested that kinetic parameters obtained from dynamic 18F-FMISO 
scanning can provide more salient information about the hypoxic regions than static images 
taken 2-4 hours post-injection (94). Even so, as kinetic analysis is not necessarily standard 
in the clinical setting, this chapter restricts itself to considering the case where two static 
frames are acquired, one pre-injection of 18F-FDOPA and one post-injection.  
The additional error introduced when performing dual-tracer imaging is dependent on the 
stabilizing time of the first tracer (18F-FMISO), tracer dynamics and the isotope half-life. 
Many of these factors can be controlled, implying that error can be mitigated by the 
appropriate design of the injection and scanning protocol. Hence, a trade-off between 
logistics and signal accuracy exists. In the proposed approach, simulations covering ranges 
of known temporal distributions of 18F-FMISO and 18F-FDOPA are generated and realistic 
levels of noise are added. The contrast and bias for a range of dual-tracer imaging protocols 
are compared to imaging on separate days to investigate the effect of dual-tracer imaging. 
The framework is demonstrated using both theoretical simulations of uptake in glioma and 
real image data obtained from a preclinical study. 
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Materials & Methods 
Modelling of PET activity using Kinetic Models 
The temporal evolution of a radiotracer can be simulated using time activity curves (TACs), 
derived from kinetic parameters previously calculated. For example, previous reports have 
shown that tracers such as 18F-FMISO and 18F-FDOPA activity concentrations can be 
modelled within the brain using irreversible two-compartment and reversible two-
compartment models, respectively (95, 96). Kinetic analysis is frequently formulated as the 
numerical solution to a set of ordinary differential equations taking reaction rate constants 
that model inter-compartment flow, k1 to k4, as parameters: 
 
𝑑
𝑑𝑡
(
𝐶1
𝐶2
) = (
𝑘1 −𝑘2 − 𝑘3 𝑘4
0 𝑘3 −𝑘4
)(
𝐶𝑝
𝐶1
𝐶2
) 3-1 
 
A two compartment model is illustrated in 3-1Figure 3-1. To model irreversible activity, k4 
is set to zero. The plasma concentration, Cp, does not necessarily include all of the activity 
in the blood, which may also contain metabolites. Thus, the blood concentration, Cb, is 
modelled as an additional variable, related to Cp. The time activity curve is obtained by 
linearly combining the compartments with the blood concentration to obtain the activity 
concentration(C) of the tracer at a given point in time: 
 
 𝐶(𝑡) = 𝐶𝑏(𝑡) + 𝐶1(𝑡) + 𝐶2(𝑡) 3-2 
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Figure 3-1 A model with three compartments. Cb(t), C1(t) and C2(t) represent activity concentration as a function of time in 
the blood, metabolic compartment one and metabolic compartment two, respectively. Cp(t) is the activity concentration of 
the tracer within the plasma, a fraction of blood activity determined by the metabolite fraction (α) calculated using Figure 
3-3 and Figure 3-4. The kinetic parameters k1, k2, k3 and k4 are reaction rate constants representing the flow between 
compartments defined by real data, and depend on the tracer and tissue combination. k4 is set to zero for irreversible 
models. 
 
In some studies, the plasma concentration is obtained using arterial blood sampling. 
However, this is invasive and sometimes impractical to obtain clinically, especially if 
patients are severely ill. Hence Cb can be estimated from an available image by averaging 
the activity in the hottest voxels within the carotid arteries, and a previously established 
model for the relationship between Cb and Cp can be used(96): 
 𝐶𝑝(𝑡) = (1 − 𝛼)𝐶𝑏(𝑡) 3-3 
 𝛼 = 0.6(1 − 𝑒−0.08𝑡) − 0.1𝑒0.01𝑡 3-4 
where t represents the time after injection of the tracer in question and 𝛼 represents the 
fraction of metabolites in the blood. Treating Cb and Cp as separate variables is necessary 
because in long scans, metabolites of tracers such as 18F-FDOPA form a significant fraction 
of activity (96). Radiolabeled metabolites of the parent tracer are a problem for quantitative 
analysis of 18F-FDOPA PET images, as they confound the true uptake of the parent tracer 
in the tissue. Therefore, correction of the 18F-FDOPA PET signal is necessary. Where 
arterial sampling is unavailable (as is typical in hospital environments) empirical correction 
from population based measurements can be used, albeit with the assumption that 
metabolites accumulate at similar rates across the population. For the FDOPA signal the 
empirically established Equation 3-4 from Schiepers et al., with equation constants adopted 
from Huang et al (96, 97), was used.  18F-FMISO metabolites within the blood are assumed 
to be negligible, due to the long post injection delay relative to the tracer kinetics. 
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For 18F-FDOPA, blood activity concentration was obtained from post-processed patient 
PET data with metabolite correction performed as per 3-3 and 3-4. A “training” 18F-FMISO 
scan was not available, so the 18F-FDOPA blood activity concentration was directly reused 
for 18F-FMISO. This makes the assumption that, although the main clearance pathway of 
18F-FMISO differs from 18F-FDOPA (renal for 18F-FDOPA(98); hepatobiliary for 18F-
FMISO(99)), the rapid drop off in blood activity is comparable to that of 18F-FDOPA.  
 
Table 3-1 - Kinetic reaction rate constants used for simulation of 18F-FDOPA and 18F-FMISO time activity curves for “typical” 
biological scenarios. Constants for 18F-FDOPA were obtained from available clinical data and constants for 18F-FMISO 
were obtained from literature(100). 
Variable  FMISO- 
“Hypoxic” 
FMISO+ 
“Normoxic” 
FDOPA+ 
“Tumour” 
FDOPA- 
“Normal/Cerebellum” 
Typical uptake [SUV]  0.95 (101) 1.1 (101) 2.7 (37) 1.1 (37) 
k1 0.300 0.300 0.225 0.124 
k2 0.450 0.450 0.169 0.199 
k3 0.008 0.001 0.031 0.075 
k4 0 0 0.016 0.010 
 
Regarding terminology, several terms are used to refer to signal measurement and need 
explanation. Activity concentration, refers to the concentration of the tracer at a given point 
in time, C(t). Total counts or signal intensity, I(t), is used to define the activity concentration 
integrated over a given time period, such as a PET frame or PET scan: 
 
𝐼(𝑡𝑠𝑡𝑎𝑟𝑡 , 𝑡𝑒𝑛𝑑) = ∫ 𝐶(𝑡) ∙ 𝑒
−λ𝑡 𝑑𝑡
𝑡=𝑡𝑒𝑛𝑑
𝑡=𝑡𝑠𝑡𝑎𝑟𝑡
, 
3-5 
where λ is the decay constant of the tracer  (or ~ln(2)/110 minutes for 18F). The defined 
terms are used to refer both to individual voxels and regions of interest, the latter of which 
is equivalent to integrating over a volume. Experiments were performed both at the voxel 
scale and over entire regions of interest; the scale is indicated in each case.  
Each tracer is simulated independently using kinetic parameters shown in Table 3-1. An 
injection interval (T) is added to the 18F-FDOPA simulation (by pre-concatenating the 18F-
FDOPA simulation with zeros) and the two simulations are summed as illustrated in Figure 
3-2. The scanning time after injection of 18F-FDOPA is symbolised by Tpost. In the 
convention used here, t = 0 indicates the time of injection for the first tracer. A second time 
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factor, τ, is used to define a time interval between the commencement of scanning and the 
second injection. In this work, the signal intensity during two time intervals is of interest: 
A single frame prior to injection of 18F-FDOPA, where solely 18F-FMISO is responsible for 
the signal: 
𝐼𝐹𝑀𝐼𝑆𝑂 = 𝐼(𝑡 − 𝜏, 𝑡) 
A single frame after injection of 18F-FDOPA, where both tracers are responsible for the 
signal: 
𝐼𝑐𝑜m𝑏𝑖𝑛𝑒𝑑 = 𝐼(𝑡, 𝑡 + 𝑇𝑝𝑜𝑠𝑡). 
 
Figure 3-2  - Example of time activity curves for a single voxel in hypoxic tumour tissue illustrating the combination of 18F-
FMISO and 18F-FDOPA activity when performing dual-trace imaging. 
 
After activities for each of the two signals are computed, measurement noise is introduced. 
Previous studies report that noise within iteratively reconstructed dynamic PET images 
follows a multivariate log-normal distribution (102, 103). However, at higher counts this 
distribution is approximately Gaussian, which has been used previously to simulate noise 
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in reconstructed PET signals (89, 100, 104-106). In this study, noise is introduced by 
sampling from a Gaussian distribution with standard deviation, σ, equal to:  
 
𝜎 = 𝑐√
𝐼𝑒𝜆𝑡
∆𝑡
, 3-6 
where the noise constant c is used to account for the noise characteristics of the scanner 
being used and Δt is the frame duration. Once again, I is used to represent the PET frame. 
The scanner specific constant c is a scalar used to control for differences in scanner 
sensitivity. It can be estimated by performing kinetic analysis on data and comparing the 
fits, F, to the original activities: 
 
𝑐 =  ℳ
{
 
 
𝜎(𝐼 − 𝐹)
√𝐼𝑒
−𝜆𝑡
∆𝑡 }
 
 
, 
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The noise constant was obtained by performing a two compartment kinetic analysis of a 
dynamic 18F-FDOPA scan. Only image regions above a given threshold were processed in 
this way. The threshold was selected to ensure the entire head was included but air was 
excluded. The sum of square error between the data and the best kinetic analysis fit was 
computed throughout the volume. The error volume was examined for high error regions, 
which were indicative of poor fits and these regions were excluded. Finally image intensity 
and the fit errors were summed over the remaining regions to solve for the noise constant, 
c, using 3-6. From this analysis, a value of 104.5 was found. Wang et al (100) used a value 
of 150. 
Quantifying the error induced by combining two signals 
To represent the biological variations typical of heterogeneous tumours, four representative 
scenarios were considered, schematically illustrated in Figure 3-3: hypoxic tumour tissue 
(high mean activity for both tracers), hypoxic non-enhancing tumour tissue (high mean 
activity of 18F-FMISO only), normoxic tumour (high mean activity of 18F-FDOPA only), and 
normal brain tissue (low mean activity for both tracers).  
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Figure 3-3 - Four broad categories of 18F-FDOPA and 18F-FMISO activity: (a) normoxic tumour, (b) hypoxic tumour tissue, 
(c) normoxic brain tissue and (d) hypoxic non-enhancing tumour tissue tissue. 
 
For each biological scenario, signal fidelity was assessed in four ways: 
 the ability to distinguish high and low 18F-FMISO uptake (hypoxic and normoxic 
tissue) using relative contrast, 
 the ability to distinguish high and low 18F-FDOPA uptake (tumour and normal tissue) 
using relative contrast, 
 the bias in18F-FDOPA measurements caused by residual dynamics within the 18F-
FMISO signal, and 
 the additional variance in 18F-FDOPA measurements arising from 18F-FMISO 
activity.  
Relative contrast between two tissues was measured in units of standard deviations of 
noise of the higher magnitude signal: 
 
𝑆 =
|𝐼1 − 𝐼2|
max (𝜎(𝐼1), 𝜎(𝐼2))
. 3-8 
Where I1 and I2 are the counts in the PET frame of the two tissues in question. This contrast 
measure was selected because it is normalised to the variations in noise arising from 
changes in signal intensity, which are in turn dependent on the choice of protocol. This 
choice of S allows the contrast for the continuum of protocols (in T and τ) and associated 
variations in signal intensity and noise to be presented in a single plot.   
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For comparison, tissue contrast values in the literature were adopted for 18F-FMISO and 
18F-FDOPA (37, 101). SUV values from these studies were converted to activity in units of 
counts: 
 
𝐴 =
𝐼𝑛𝑗𝑒𝑐𝑡𝑒𝑑𝐷𝑜𝑠𝑒[𝐵𝑒𝑞𝑙]∗𝑆𝑈𝑉[𝑅𝑂𝐼]∗𝑒λ
(𝑡𝑒𝑛𝑑+𝑡𝑠𝑡𝑎𝑟𝑡)
2 ∗(𝑡𝑒𝑛𝑑−𝑡𝑠𝑡𝑎𝑟𝑡)[𝑠]∗𝑉𝑜𝑥𝑒𝑙𝑉𝑜𝑙𝑢𝑚𝑒[𝑚𝑙]
𝑃𝑎𝑡𝑖𝑒𝑛𝑡𝑊𝑒𝑖𝑔ℎ𝑡[𝑔𝑚]/𝐷𝑒𝑛𝑠𝑖𝑡𝑦𝑂𝑓𝑊𝑎𝑡𝑒𝑟[𝑔𝑚/𝑚𝑙]
, 3-9 
Reported 18F-FMISO standard uptake values (SUV) for hypoxic and normoxic regions were 
of 1.1 and 0.95 respectively in Eschmann et al (101). The adopted 18F-FDOPA SUV for 
tumour and normal tissue were 2.7 and 1.1 respectively from Pafundi et al (37). Here, a 
patient weight of 80kg is assumed. Activities were converted to contrasts using 3-5, 
resulting in 18F-FMISO and 18F-FDOPA baseline contrasts shown in the bottom rows of 
Error! Reference source not found. for reference (in the results). To represent the worst 
ase for a range of T and τ values, the contrast between low and high 18F-FMISO uptakes 
were measured with high 18F-FDOPA background, i.e. quadrants A and B in Figure 3-3. 
Also, the contrast between low and high 18F-FDOPA uptakes were measured with high 18F-
FMISO background, i.e. quadrants B and D in Figure 3-3, for a range of T and τ values. 
Bias in the 18F-FDOPA signal can arise from residual dynamics in the 18F-FMISO signal for 
the case where the 18F-FMISO activity was assumed to be static. The bias is expressed as 
a percentage of the original 18F-FDOPA signal and this effect is assessed for a hypothetical 
tissue expressing a high 18F-FMISO activity with the lower 18F-FDOPA activity typical of 
healthy (cerebellum) tissue, i.e. quadrant D in Figure 3-3. Tissues expressing these 
properties have longer 18F-FMISO dynamics and lower 18F-FDOPA signal, and so act as a 
“worst case” scenario. 
Finally, the additional variance introduced by background 18F-FMISO uptake to the 18F-
FDOPA signal was measured. This error is expressed as a percentage of the original 18F-
FDOPA signal and, as above, is assessed for a hypothetical tissue expressing a high 18F-
FMISO activity with the lower 18F-FDOPA activity typical of normal (cerebellum) tissue 
(quadrant D in Figure 3-3). 
To assist discussion, several T-τ pairs are used as reference protocols. Several studies 
into hypoxia have used acquisition time of 20 minutes dictating one choice of  (47-49, 
107). Minimising  allows for the optimal use of scanner time, and thus  = 1 minute was 
investigated as well. 18F-FMISO stabilizing times of 2 hours and 4 hours post-injection have 
been proposed (47-49, 107, 108). Reducing the 18F-FMISO stabilizing time also has 
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logistical implications, so a 30-minute 18F-FMISO stabilizing time is also investigated. 
Hence three references for T were used: 0.5, 2 and 4 hours. These were combined with 
the two τ durations (1 and 20 minutes) to give six reference scenarios. Preclinical scans 
were used in addition to theoretical experiments to assist in validation. In the preclinical 
scans, T=120 minutes, so two additional protocols are used for reference: τ = 5, T = 120 
and τ=10, T=120 minutes to give a total of eight reference protocols. The eight reference 
protocols each comprise a single point in a continuum of variations of T and τ, and are 
shown in columns two and three of Error! Reference source not found. in the results. 
Imaging protocol 
The assumed scenario is that the patient is injected with 18F-FMISO and rests in a waiting 
room while 18F-FMISO activity stabilises. Several minutes before injection of 18F-FDOPA, 
the patient is placed prone on the scanner bed. Following a transmission CT scan, PET 
acquisition is initiated. After the pre-defined interval, τ, the 18F-FDOPA bolus is injected 
while scanning continues. The patient would need to remain prone and not move. If 
movement does occur, registration is possible if enough anatomical structure is visible in 
the first image, or multiple CT scans are performed. The time of injection after scanning 
commences is recorded to allow the correct separation of the two static frames (pre- and 
post-injection of 18F-FDOPA). For 18F-FMISO, a dosage of 3.7 MBq/kg was adopted in 
previous studies (46, 48). For 18F-FDOPA an activity of 2.05 MBq/kg is typical of the 
literature and the authors’ institution and was assumed in this work (96). In the experiments, 
the total acquisition time is the 18F-FMISO-only interval plus combined tracer interval, i.e. τ 
+ Tpost. For the simulations Tpost was assumed to be 75 minutes. 
Several studies have shown that a static scan several hours post-injection suffices to 
identify hypoxic regions that retain 18F-FMISO (28, 46, 48, 49, 63, 109-112). Two to four 
hours post-injection, biological steady state has been reached, hence the relatively stable 
signal. Thus, although an irreversible two-compartment model is used to simulate 18F-
FMISO signals, measurements of signal intensity are estimated assuming static activity 
during the time interval prior to injection of 18F-FDOPA, τ, shown in Figure 3-2.  
The assumption of static activity is in accord with several papers (28, 46, 48, 49, 63, 109-
112) when reporting on 18F-FMISO scans. The slow variation in 18F-FMISO activity arises 
from the biological properties of hypoxic tissue, which prevents it from being metabolised 
and expelled. In normally oxygenated tissue 18F-FMISO remains unbound, so the extended 
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interval between injection and scan ensures little, if any, unbound tracer remains. To 
reiterate, recent work has suggested kinetic parameters can provide more salient 
information about the hypoxic regions (94). The use of a static 18F-FMISO frame several 
hours post injection is a trade-off to limit the amount of scanning time required. 
The effects of varying dose and attenuation 
Increasing the injection dose increases activity, and hence improves signal discrimination. 
However, protocols seek to avoid excessive radiation dose to the patient. The effect of 
dosage on signal discrimination was investigated by identifying for which T and  there 
were above the baseline contrasts in the literature for individual voxels. 
Similarly, signal attenuation varies with spatial location due to the density of the surrounding 
tissue. For completeness, typical attenuation values were obtained from a real CT scan of 
the human head using a GEANT4 (version 9.6.1) Monte-Carlo simulation as follows (113, 
114). This approach was used, as opposed to measurements from a phantom, to check 
the extent to which skull thickness influenced attenuation as a function of spatial location. 
Multiple adjacent rings of detectors, each comprised of many crystals with the same 
geometry and arrangement as the Philips Gemini GXL scanner, were positioned around a 
3D patient CT dataset. The full decay scheme of 18F was simulated, with all radioactive 
decay products tracked throughout the CT dataset until either leaving the simulated 
scanner or hitting a detector. Atoms of 18F were released and triggered to decay on a 200 
mm cubic grid about the PET gantry centre at intervals of 5 mm in each of the 3 orthogonal 
directions. Ten thousand atoms were released at each point on the grid and an energy 
histogram of annihilation photons reaching the ring of detectors was scored. The two areas 
of minimum and maximum attenuation were identified and used to attenuate the simulated 
signals.  This allowed for an observation of the effect of attenuation due to tissue density 
in both the least severe and most severe cases, providing for an estimation of the possible 
effects of attenuation on dual-tracer protocols.  
Experiments using (real) preclinical data 
As a proof of concept experiment, an investigation was performed using images of a 
NOD/SCID mouse bearing a U87 glioma cranial xenograph in the right striatum. U87 cells 
were maintained in RPMI160 medium (Gibco) supplemented with 10 % foetal bovine serum 
(Gibco), 2 mM L-glutamine, 25 mM HEPES, 25 mM sodium bicarbonate, 100 μg/mL 
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penicillin and 100 μg/mL streptomycin. Cells were cultured in 5 % CO2 / 95 % humidified 
air atmosphere at 37 °C and used when they reached 70-80 % confluence.  Cells (100,000 
in 2 μl of PBS) were injected into the right striatum of 6-week old female NOD/SCID mice 
using a stereotaxic frame under isoflurane anaesthesia.  Cells were injected at a depth of 
3 mm, 1.6 mm caudal and 0.8 mm lateral to the bregma. 
All animal experiments were approved by The University of Queensland Animal Ethics 
Committee. For synthetic dual-tracer experiments, mice were injected with tracer (5-7 MBq) 
intravenously via the lateral tail vein under isoflurane anaesthesia. Mice were maintained 
under 1-2 % isoflurane in an air-oxygen mixture at a flow rate of 2 L/min for the duration of 
the imaging session and monitored by a breathing pillow.  Mice were positioned on the 
scanner bed (Bruker 7T Clinscan interfaced with a Siemens Spectrometer running 
Numaris/4 VB17 with a PET ring centred at the isocentre of the magnet consisting of 3 
rings of 16 crystal blocks). 30 minute 18F-FMISO and 18F-FDOPA images were acquired on 
separate days, with the interval between scans large enough to allow complete washout 
and decay of the first tracer. For 18F-FMISO, the 30 minute scan was acquired 120 minutes 
post-injection to reflect T = 120 minutes, allowing coverage of a range of scenarios. The 
preclinical data was used to perform a synthetic combination of the two data sets in list-
mode format and subsequent separation after image reconstruction of two frames, one 
before and one after 18F-FDOPA injection (i.e. when counts from the 18F-FDOPA list mode 
file begin to be included). No spatial registration was performed in this experiment, as no 
software for list-mode registration was available. Hence no assumptions of biological 
correspondence could be made. However this does not obstruct the goal of this experiment, 
which was to ascertain the effect of dual-tracer imaging on the fidelity of the signals of the 
two signals. Therefore, only measurements in terms of signal fidelity were performed, and 
the original independently reconstructed images were used as a basis for analysis. In the 
real-world experiments no ground truth is available. At best, it can be assumed that the 
signal is the best estimate of PET activity that can be obtained with the hardware, albeit 
with error bounds that can be established. Hence experiments attempted to estimate bias 
with respect to the non-dual-tracer PET reconstructions (i.e. not the ground-truth) and that 
the variance in the signal estimates did not increase materially. Also given the manner in 
which PET scanners are read, where clinicians identify hyper-intensities within a noisy 
background sometimes in comparison to contralateral regions, results were usually 
reported in terms of contrast in units of signal standard deviation (which implicitly accounts 
for noise). 
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The list mode data were interleaved to reproduce the effect of dual-tracer imaging and then 
reconstructed using the original scanner software to produce images of the mouse. The list 
mode format was kindly supplied by Siemens (115). The 18F-FMISO stabilizing time (T) 
was kept constant at 120 minutes and the pre-18F-FDOPA scanning interval () was set at 
1, 5, 10 and 20 minutes, identical to a selection of the reference protocols. Tissue contrast 
and 18F-FDOPA signal error were measured and reported for selective reference protocols. 
Although no spatial registration was performed, care was taken to ensure that the mouse 
was secured in the same position for both scans to maximise spatial alignment. Some 
movement did occur, but alignment was sufficient to ensure that synthetic exemplars of all 
permutations of low/high 18F-FMISO/18F-FDOPA occurred. Regions corresponding to 
hypoxic and normoxic 18F-FMISO and tumour and normal 18F-FDOPA uptake were 
manually drawn on the pre-clinical scans. Mean tissue signal was measured for the ROIs 
and the contrast of hypoxic-normoxic (18F-FMISO) and tumour-normal (18F-FDOPA) 
tissues was calculated and compared to simulated results. The fidelity of 18F-FDOPA 
signals extracted from synthetically combined data was compared to the true signals and 
errors were reported as percentage of the true 18F-FDOPA signal. Since the ROI mean 
activity (rather than summed activity) was used to calculate contrast, it is equivalent to a 
(class standardised) voxel level analysis.  
In addition, an analysis of the individual voxels was performed on the preclinical data set 
within the ROIs defined above. Voxel values for true, single-tracer data was plotted against 
separated voxel values to examine their agreement with each other.  
Results 
The experiments described in the previous section can be summarised as follows: 
 theoretical simulations using parameters derived from human images to establish 
the range of protocols giving sufficient signal fidelity at the voxel scale in Figure 3-4, 
Figure 3-5 and Error! Reference source not found. 
 theoretical examination of the effects of varying dose in Figure 3-6 at the voxel scale 
 separation of preclinical data synthetically combined in the list-mode format in Figure 
3-7 and Table 3-3 for regions of interest means, and in Figure 3-8 and Figure 3-9 for 
individual voxels. 
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Theoretical experiments 
The contrast between hypoxic-normoxic tissues and tumour-normal tissues is presented 
as a function of pre-18F-FDOPA scanning interval, τ and 18F-FMISO stabilization time, T in 
Figure 3-4. In Figure 3-4a, for each specific τ, a distinct optimum 18F-FMISO stabilization 
time is visible. 18F-FDOPA contrast improves as T increases, as shown in Figure 3-4b, 
while the pre-18F-FDOPA scanning interval, , has a negligible effect.  
The bias in the measured 18F-FDOPA activity induced by residual 18F-FMISO dynamics, 
presented in Figure 3-5a, decreases as the margin between stabilisation time and scanning 
interval increases. The cumulative improvements reduce with further increases in margin. 
The effect is expressed as a percentage of the simulated 18F-FDOPA activity before noise 
is introduced. On the other hand, 18F-FDOPA variance in Figure 3-5b, decreases both as 
T and τ increase, because increasing the scanning interval improves the accuracy of the 
estimate of 18F-FMISO-activity and increasing the stabilising time reduces the 18F-FMISO 
signal and hence its effect on 18F-FDOPA. For the eight reference protocols, tissue contrast 
and 18F-FDOPA error due to both 18F-FMISO dynamics and statistical noise are shown in 
Error! Reference source not found.. For comparison, tissue contrasts for single-tracer 
imulations are also shown. In all cases, although the 18F-FDOPA contrast decreased when 
performing dual-tracer imaging, the contrast exceeded the reference contrast from the 
literature. The 18F-FMISO contrast required a scanning period of at least 10 minutes to 
reach the reference contrast from the literature, assuming scanner sensitivity similar to a 
Phillips Gemini. For reference, the noise standard deviation, as calculated by 3-6, for each 
reference protocol is shown in Error! Reference source not found.. 
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Table 3-2 - Full set of results from simulations for the eight reference protocols identified (a), which represent the imaging protocols, shown in (b). Contrasts are reported using units of 
noise standard deviations as an indication of ability to unambiguously separate adjacent voxels. Tissue contrasts for dual-tracer signals (c; after signal separation) are compared to 
single-tracer signals (d) for the same protocols. Note that tissue contrasts for 18F-FMISO are identical for single- and separated-tracer contrasts, as the 18F-FMISO scan is performed 
prior to the injection of 18F-FDOPA, and is therefore unperturbed by dual-tracer imaging. Simulation signals and corresponding noise standard deviations, calculated from 3-6, are also 
shown for each reference protocol simulation to illustrate signal intensities (e). The right-most columns show the bias in the 18F-FDOPA signal due to residual dynamics in the 18F-FMISO 
signal (f), and the variance in the 18F-FDOPA signal due to the additional noise introduced by the 18F-FMISO signal (g). Contrasts obtained from the literature are also shown for 
comparison.  
(a) (b) (c) (d) (e) (f) (g) 
Ref. 
Protocol 
Interval (min) 
Dual Tracer Contrast 
(standard deviation of noise; 
higher is better) 
Single Tracer Contrast (standard  
deviation of noise; higher is 
better) 
Signal (Noise Standard Deviation; 
higher is better 3-6) 
FDOPA Bias 
due to FMISO 
dynamics (% 
of FDOPA 
signal; lower is 
better) 
Additional 
FDOPA 
Variance due 
to FMISO 
noise (% of 
FDOPA signal; 
lower is better) 
T  
(Injection 
interval) 
 
  
(FMISO 
scanning 
time) 
FMISO 
hypoxic-
normoxic 
tissue 
FDOPA 
tumour-
normal 
tissue 
18F-FMISO 
hypoxic-
normoxic 
tissue 
18F-FDOPA 
tumour-normal 
tissue 
18F-FMISO 
Hypoxia 
[counts] 
18F-FDOPA 
Tumour 
[counts] 
1 30 1 
Same as 
single tracer, 
because 
estimate 
prior to 
FDOPA 
44.58 0.36 
51.8 
183(183) 
15570 
(297) 
9.46 35.65 
2 120 1 46.95 0.58 163(148) 2.49 22.86 
3 240 1 47.77 0.49 146(136) 0.45 14.87 
4 30 20 44.58 2.78 4320(199) 17.9 7.68 
5 120 20 46.95 6.79 2483(151) 3.40 4.86 
6 240 20 47.77 5.82 2041(137) 0.62 2.87 
7 120 5 46.95 1.90 606(149) 2.67 14.86 
8 120 10 46.95 3.53 1222(150) 2.99 11.87 
 Baseline Values from the literature 
Bib. Ref. 
(101) 
120 14 Unavailable 3.40  SUV = 1.1 (normal)/0.95 (hypox.) 
Bib. Ref. 
(37) 
10 20 Unavailable  35.80 SUV = 2.7 (tumour)/1.1 (normal) 
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Figure 3-4 - a) Contrast between 18F-FMISO signals in hypoxic and normoxic tissue types at a range of T and  values. 
Higher contrast is better. Results are reported using units of noise standard deviations, as an indication of ability to 
unambiguously separate adjacent voxels. The grey triangle at the bottom of the image indicates protocols (Beginning scans 
prior to injection of 18F-FMISO adds no information). b) Contrast of tumour and normal tissue based on 18F-FDOPA activity 
for various T and  values. Higher contrast is better. Results are reported in units of noise standard deviations of the larger 
signal (18F-FDOPA). 
 
 
Figure 3-5 - a) Bias in the 18F-FDOPA normal tissue signal imposed by residual dynamics in the 18F-FMISO signal in hypoxic 
regions for various T and  values. Bias is shown as percentage of the simulated 18F-FDOPA signal. 18F-FDOPA defined 
normal and 18F-FMISO defined hypoxic tissue was chosen due to the low activity of 18F-FDOPA and long dynamics of 18F-
FMISO signal, representing the worst-case scenario. b) Additional variance in the 18F-FDOPA normal tissue signal added 
by the background 18F-FMISO activity.  
 
The effect of varying dose and attenuation 
The improvements in 18F-FMISO contrast resulting from increased 18F-FMISO dosage are 
presented in Figure 3-6a. Here, contours were used to represent baseline contrasts for 18F-
FMISO taken from the literature. Increased 18F-FMISO dose gives increased flexibility in 
the choice of protocol, i.e. T and τ can be reduced. Attenuation has a similar effect to 
varying 18F-FMISO dose, as it also affects the measured signal by decreasing the signal-
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to-noise ratio. However the effects are smaller than that of dose as shown in Figure 3-6b. 
  
 
Figure 3-6 - a) The effect of varying injected 18F-FMISO dose on the 18F-FMISO iso-contrast line having the baseline 
contrast. b) The effect of attenuation for tumour and normal tissue. The lines shown are iso-contrast contours with the 
baseline contrast. 
Validation using synthetic combination of list-mode data 
This method was validated by applying it to a synthetically combined dual-tracer mouse 
model bearing a U87 xenograph in the right striatum. Results are shown in Figure 3-7 and 
Table 3-3 for reference protocols 2, 5, 7 and 8. The white outlines in Figure 3-7b and Figure 
3-7c show activity in the olfactory system and salivary glands which were specifically 
excluded from statistical analysis. Two regions of interest within the brain were selected on 
each PET scan for a later experiment (Figure 3-8).  
Figure 3-7b-c show the true 18F-FMISO and 18F-FDOPA data, which were acquired 
independently on separate days. Figure 3-7d shows this dual-tracer data. Since registration 
was not performed, no biological analysis can be made, only an analysis of signal fidelity. 
In rows 2-5, the three columns respectively show the measured 18F-FMISO activity, the 
estimated 18F-FDOPA activity and the error in the 18F-FDOPA estimate. Each row shows 
the results for τ ranging from 1 to 20 minutes. 
18F-FDOPA signal fidelity increases with increasing τ, but the decrease in error drops off 
after τ = 10 minutes, which is in accordance with findings in simulations. The quality of the 
18F-FMISO signal also increases with increasing τ.  
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Table 3-3 outlines the contrast of hypoxic-normoxic and tumour-normal tissues for 
reference protocols 2, 5, 7 and 8. Results from single-tracer scans (independently 
reconstructed) and simulation results are also shown for comparison. 
For the 18F-FMISO image, the selected regions of high and low 18F-FMISO uptake are 
respectively indicated by magenta and green contours in Figure 3-7b. A voxel-wise 
comparison of the true and estimated 18F-FMISO activity concentration is shown for each 
region in Figure 3-8 row 1, and using the same identifying colours. For the 18F-FDOPA 
image, the selected regions of high and low metabolism are respectively indicated by the 
blue and red contours in Figure 3-7c. A voxel-wise comparison of the true and estimated 
18F-FDOPA activity concentration is shown for each of these regions in Figure 3-8 row 2, 
using the same identifying colours. At the voxel scale, the increases in relative bias and 
variance as the scanning interval (and hence activity) decreases are especially apparent 
for 18F-FMISO, but are visible in 18F-FDOPA as well.  
In addition, to ensure that pre-clinical dual-tracer data reflects a large range of possible 
variations in signal, voxel activities for 18F-FMISO are plotted against those of 18F-FDOPA 
in Figure 3-9. All four permutations of signal strength shown in Figure 3-3 exist, indicating 
that the preclinical experiments have adequate coverage of the scenarios in Figure 3-3, 
and assuring that analysis can be performed without the need for spatial registration on the 
list-mode data. 
 
Table 3-3 - Contrasts in 18F-FMISO and 18F-FDOPA signals for varying Pre-18F-FDOPA scanning interval in simulated dual-
tracer imaging of NOD/SCID rodent implanted with U87 xenograph. Also shown are contrasts from single-tracer data, 
obtained from the independently reconstructed scans, and dual-tracer-tracer contrasts from Table 3-1 for hypoxic-normoxic 
and tumour-normal tissue for the same protocols. The mean activity from each voxel was used.   
Reference 
Protocol 
Interval 
(minutes) 
Dual-Tracer Mouse 
Data Contrast (% noise 
std. dev.) 
Single-Tracer Mouse 
Data Contrast (% noise 
std. dev.) 
Simulated Dual-Tracer 
Contrast (% noise std. 
dev.) 
T  
FMISO 
“hypoxic-
normoxic” 
tissue 
FDOPA 
“tumour-
normal” 
tissue 
FMISO 
“hypoxic-
normoxic” 
tissue 
FDOPA 
“tumour-
normal” 
tissue 
FMISO 
“hypoxic-
normoxic” 
tissue 
FDOPA 
“tumour-
normal” 
tissue 
ROI → 
  
Magenta Green Red Blue   
2 120 1 
Same as 
single 
tracer. 
49.56 0.61 
57.17 
0.58 46.95 
7 120 5 51.79 2.21 1.90 46.95 
8 120 10 55.94 3.98 3.53 46.95 
5 120 20 58.48 7.33 6.79 46.95 
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Baseline contrast values from literature 
(101)  120 14   3.40    
(37) 10 20    35.80   
  
Figure 3-7 - Example dual-tracer imaging of 18F-FDOPA and 18F-FMISO signals acquired on a NOD/SCID mouse bearing 
a U87 glioma xenograph in the right striatum. The original 18F-FMISO and 18F-FDOPA signals (b and c, respectively) are 
interleaved using list mode data to simulate a dual-tracer acquisition (d). An 18F-FMISO stabilizing time (T) of 120 minutes 
was used. Rows 2-5 show the extracted 18F-FDOPA signal from the dual=tracer signal (f, i, l, o) for reference protocols 2, 
5, 7 and 8. The 18F-FDOPA signal is extracted by subtracting the acquired 18F-FMISO signal (e, h, k, n) from the dual-
tracer data (d). Errors in 18F-FDOPA signal (differences between true 18F-FDOPA and extracted 18F-FDOPA signal) are 
also shown (g, j, m, p). A T2 acquisition is shown in (a), indicating the location of the tumour volume. Magenta and green 
contours in (b) represent areas of high and low 18F-FMISO activity, respectively. Blue and red contours in (c) represent 
areas of high and low 18F-FMISO activity, respectively. These regions were test examples of hypoxic and normoxic (b) 
and tumour and normal (c) tissue types. The high activity shown in (b) and (c), signified by the white contours, is activity 
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due to the olfactory system and salivary glands and was not used in the analysis. Note that the subject was carefully placed 
in the same position on subsequent days, but image registration was not performed, so no biological analysis was 
performed. 
 
  
Figure 3-8 - Voxel-wise analysis of ROIs of sample data shown in Figure 3-7. Voxel values are plotted for true values (x-
axis) as obtained from the single-tracer image versus extracted values (y-axis) as obtained from dual-tracer imaging. Each 
row represents the correlation between true and extracted values for reference protocols 2, 7, 8 and 5, respectively. Blue 
lines represent the line of perfect correspondence, where voxels on this line are identical between true and extracted data 
sets. As can be seen, extracted voxel values approach true values as τ increases. Lower count values for 18F-FMISO (a, 
c, e, g) due to a lower activity result in a more varied result than that of 18F-FDOPA (b, d, f, h). Note that no biological 
correspondence should be assumed for this data because the images were not registered.  
  
   
Figure 3-9 - Voxel values for ROIs used in analysis of real mouse data within the ROIs of sample data shown in Figure 3-7. 
18F-FMISO activities are plotted (x-axis) against 18F-FDOPA activities for the same voxels. As can be seen, the range of 
voxels analysed included all four biological variations shown in Figure 3-3; 18F-FMISO positive and 18F-FDOPA negative 
representing hypoxic, non-enhancing tissue, 18F-FMISO positive and 18F-FDOPA positive representing hypoxic infiltrating 
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tissue, 18F-FMISO negative and 18F-FDOPA negative representing healthy tissue and 18F-FMISO negative and 18F-FDOPA  
positive representing normoxic infiltrating tissue.  Note: no biological correspondence should be assumed for this data 
because the images were not registered. Hence these results solely show that all the scenarios in Figure 3-3 are covered 
for the purposes of validation. 
Discussion 
The imaging of both hypoxia and metabolism using PET has the potential to provide a 
better understanding of how biological factors in tumours affect treatment outcome. Such 
an understanding could assist in deciding what biology radiation therapy dose contours 
should conform to, and whether fractionation and dose should be adapted to dealing with 
acute hypoxia, chronic hypoxia or metabolism. In the clinical setting however, the potential 
utility of multiple metabolic modalities may be outweighed by the impracticality of 
performing multiple PET acquisitions on separate days. Performing dual-tracer imaging 
could overcome many practical issues, but this comes at a cost of signal accuracy. This 
chapter provides a framework for study designers to explicitly examine the potential 
additional error encountered when performing dual-tracer imaging and provides a method 
that allows imaging of multiple tracers where the dynamics of the first tracer can be 
assumed to be static at the injection of the second.  
Unlike previous work which relies on (long) scans from the injection of the first tracer, this 
chapter focuses on a use-case more likely in clinical practice, where scanning commences 
from several minutes before injection of the second tracer and two static frames are 
reconstructed: one before and one after the second injection. Such a protocol could allow 
centers to maintain a similar patient throughput, despite using two tracers. It should be 
emphasised however, that the practicalities of synthesising two tracers on the same day 
also have additional logistical implications, which are outside the scope of this work. 
In addition to the injected activity of 18F-FMISO and 18F-FDOPA, signal activity is controlled 
by three key factors:  
 the pre-18F-FDOPA scanning interval, , 
 the 18F-FMISO stabilizing time, T, and 
 the local blood flow and tracer activity using the scaling factor, β.  
A pre-18F-FDOPA scanning interval that is too short does not allow reliable estimation of 
the hypoxic signal. For the noise model used, the signal-to-noise ratio decreases with the 
square root of the signal. Therefore, images with low intensity from short acquisitions 
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contain a higher fraction of noise compared to those of higher intensity, making them less 
statistically reliable. On the other hand, radioactive decay means that the signal intensity 
decreases after tracer injection, limiting the information gained by extending scan-time 
excessively. Hence both upper and lower limits on  exist. 
Shortening the 18F-FMISO stabilizing time, T, has two negative effects. Firstly, the unbound 
18F-FMISO tracer has insufficient time to wash out of the normoxic tissue, which can result 
in false positives. Secondly, the 18F-FMISO signal will not be at steady state when 18F-
FDOPA is injected, violating the assumption of relative stasis that allows 18F-FMISO signal 
to be subtracted from the combined signal. Dynamic changes in 18F-FMISO result in biased 
estimates of the 18F-FDOPA signal. Lengthening T allows 18F-FMISO activity to stabilize 
but has limited influence beyond a certain threshold because radioactive decay limits 
additional accumulation of 18F-FMISO counts.  
Several sets of experiments were performed to examine the range of scanning-injection 
protocols for which 18F-FMISO and 18F-FDOPA could be imaged within a single imaging 
session with sufficient accuracy. For this purpose, dynamic simulations for a range of 18F-
FMISO stabilisation intervals and 18F-FMISO-only scanning intervals were performed, 
before subsequent integration to generate static signals of mean activity.  
In the first set of theoretical experiments, the contrast between regions of high and low 
activity for 18F-FMISO and 18F-FDOPA was examined. The contrast in Figure 3-4a 
increases with scanning interval and there is a clear optimum for stabilisation interval for 
each scanning interval. This pattern arises from the trade-off between signal fidelity and 
scanning time, ensuring sufficient signal intensity from 18F-FMISO and while excluding the 
large dynamics in the 18F-FMISO signal immediately after its injection. 
Considering the 18F-FDOPA signal in Figure 3-4b, if 18F-FDOPA uptake is high, relative 
contrast always exceeds 35.80 but never reaches the baseline contrast when no 18F-
FMISO signal is present. 18F-FDOPA contrast is solely influenced by the stabilisation 
interval, because 18F-FMISO activity decreases with increasing stabilisation interval. 
Scanning intervals above 90 minutes ensure 18F-FDOPA contrasts (in high 18F-FMISO 
regions) remain high.  
The bias in the 18F-FDOPA signal shown in Figure 3-5a remains low, so long as the 
stabilising interval exceeds the scanning interval by at least 30 minutes. This restriction 
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arises, because below this threshold dynamics in the 18F-FMISO signal cause a positive 
bias in the 18F-FMISO signal and a corresponding negative bias in the 18F-FDOPA signal. 
The variance from the underlying 18F-FMISO signal is cumulative with the 18F-FDOPA 
variance in the combined signal. Since the protocol only influences the 18F-FMISO portion 
of the variance, only this is reported in Figure 3-5b. Variance decreases both as the 
scanning interval and the stabilisation interval increase. Increasing the scanning interval 
increases the accumulated 18F-FMISO counts, hence the observed decrease in variance. 
Increasing stabilisation interval decreases the 18F-FMISO signal and hence the decrease 
in variance added to the 18F-FDOPA signal. 
Scan intervals below 10 minutes have inadequate tissue contrast due to the low 
accumulation of 18F-FMISO. Insufficient 18F-FMISO counts also result in increased bias in 
the 18F-FMISO and hence 18F-FDOPA signals. The variance added to the estimated 18F-
FDOPA signal also increases. Stabilisation intervals of 120 minutes or more limit the 
variance induced in the 18F-FDOPA signal. The protocol does not substantially influence 
the contrast between regions of high and low 18F-FDOPA uptake. Thus, the limitations on 
protocol are imposed by the ability to distinguish hypoxic/normoxic regions, and limit 18F-
FDOPA bias and variance. Using contrasts from typical activity concentrations reported in 
the literature as a baseline does not impose onerous restrictions on the protocol. The 
baseline contrast levels can be satisfied by using a scanning interval of 10 minutes or more 
and a stabilisation interval that exceeds the scanning interval by at least 90 minutes, 
assuming scanner sensitivity similar to a Phillips Gemini scanner. Shorter scanning and 
stabilisation intervals would be possible on newer, more sensitive scanners. 
Considering the influence of altering the 18F-FMISO dosage, Figure 3-6a shows that the 
standard dosage can be reduced by a factor of two and still retain adequate contrast with 
changes in protocol that remain practical in certain clinical setting  (e.g. T = 120min, τ = 
25min). As shown in Figure 3-6b, the comparative influence of attenuation on the signal 
was relatively insignificant. Hence the spatial variation of attenuation within PET scans is 
of less concern when selecting protocol design. 
To assess the validity of the theoretical results, tissue contrasts were measured using real 
images acquired from a NOD/SCID mouse bearing a U87 xenograph in the right striatum. 
Results from this experiment are reported in Table 3-3, with corresponding simulation 
results also shown for comparison. Tissue contrasts were measured for the reference 
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protocols 2, 5, 7 and 8 for two sets of paired regions: hypoxic versus normoxic tissue, and 
tumour versus normal tissue. Contrasts for dual-tracer mouse data were similar to values 
obtained from the simulations, with contrasts observed larger than those obtained in 
simulations in all cases. This suggests that the dual-tracer framework using simulations 
provides a conservative estimate of the range of protocols that will maintain adequate 
contrast and limit bias and variance in the FDOPA signal. The differences in contrast in the 
theoretical experiments and those measured in the image have several possible causes. 
The dose per kilogram administered to the mouse was not the same as that assumed in 
the experiments, and the metabolism of the mouse is more rapid than that typical for 
humans. Furthermore, the stage and genotype of the tumour could also play a role, as the 
U87 tumour line is a very aggressive model, designed to produce high-grade tumours in 
short periods of time. Finally, the noise parameter, c, used in the simulations was estimated 
for the Phillips Gemini scanner, not the Siemens Inveon scanner used for the mouse 
imaging. The former was used because blood activity concentrations adequate for kinetic 
analysis could only be obtained from the 18F-FDOPA scan of humans, allowing c to be 
computed. Variations in dose and biology are typical in practice anyway, so some variation 
from simulation is to be expected. The key point when considering protocols is to ensure 
that the simulations are conservative enough that the selected protocol has some boundary 
for error, i.e. it is better to over-estimate c, and under-estimate activity concentration. 
An example slice of the dual-tracer mouse model is shown in Figure 3-7, illustrating that as 
the scanning interval is increased, so does the fidelity of the 18F-FMISO signal as well as 
the ability to extract the 18F-FDOPA signal. The effect seen in Figure 3-5 where the increase 
in signal fidelity asymptotically approaches a maximum as the scanning interval is 
increased is also evident. The increase in signal fidelity between tau=10 to tau=20 is 
significantly lower than the increased between tau=1 to tau=5.  
Voxel-wise analysis was also performed on regions defined by manually drawn ROIs. The 
voxel-wise analysis makes no assumptions about biological correspondence, as no 
registration was performed. Hence this experiment is synthetic in the sense that it 
measures signal loss only, but using real intensities and the full reconstruction pipeline that 
would be used in practice. Figure 3-8 shows that as τ increases, so does the reliability of 
the voxel values. The diagonal blue lines in the plots indicate the ideal case. The results in 
Figure 3-5, Figure 3-7 & Figure 3-8 show that for pre-18F-FDOPA scanning intervals greater 
than 10 minutes, dual-tracer voxel values give similar values to the single-tracer case.  
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The analysis in the experiments is limited to four biological scenarios that were obtained 
from the literature. These scenarios were chosen to cover the typical range of possible 
biology under investigation and concisely define the trade-off between signal fidelity and 
clinical logistics. To show that real data analysis covered all four biological variations 
identified, 18F-FMISO and 18F-FDOPA voxel values for manually drawn ROIs were plotted 
in Figure 3-9. As shown, the ROIs from real mouse data covered a wide range of biological 
variations. It is conceivable that future work will reveal biological conditions outside the 
range of conditions tested here. In this event, the analysis could be repeated for the 
additional biological scenarios. 
Residual dynamics will induce some bias, if a static FMISO signal is assumed. The bias 
depends on the FMISO gradient, which at one hour is relatively low hence the positive 
results reported here. These dynamics can be caused by the continued supply of remaining 
tracer from the blood. Figure 3-2 shows possible time activity curves generated using the 
adopted kinetic parameters and the blood activity concentrations shown in Figure 3-10a. 
However, some studies have shown continual binding of FMISO to hypoxic cells up to and 
past two hours post injection. Hence, for completeness, the experiments were performed 
again with the blood activity concentration shown in Figure 3-10c. Results from these 
experiments showed improved signal separation, suggesting that, although residual 
dynamics will affect the separability of these tracers, the results shown here are sufficiently 
conservative to represent possible residual 18F-FMISO dynamics. Although the induced 
bias is low, accounting for FMISO gradient in the model has the potential to allow the 
injection interval to be reduced, and will be investigated in future work. 
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Figure 3-10 - Variations of the blood activity concentration (BAC) that allow simulation of different 18F-FMISO dynamics. 
The BAC shown in a) was adopted for this study and results in an 18F-FMISO time activity curve (TAC) where visual 
dynamics are due to wash out of the tracer from the diffused compartment. Simulation of 18F-FMISO using b) results in a 
perfectly static TAC. Simulation using c) results in a 18F-FMISO TAC where constant biding of 18F-FMISO within the cell 
(wash in to the trapped compartment) can be simulated. Experiments were also performed using this BAC, with results 
showing better tissue separation than a)  
 
Recent work has suggested that kinetic parameters obtained from dynamic 18F-FMISO 
scanning can provide more salient information about the hypoxic regions than static images 
taken 2-4 hours post-injection (94). While this approach may hold potential for providing 
additional information, the literature suggests that a short static scan suffices for 
identification of hypoxic regions (63, 78, 79). Also, the addition of a dynamic 18F-FMISO 
scan to that of a dynamic 18F-FDOPA scan would require a total dual-tracer acquisition in 
excess of 3 hours, which is not acceptable in many clinical settings. 
It is important to note that the noise level within a signal is proportional to not only tracer 
activity, but also the scanner sensitivity. The experiments all assume performance 
equivalent to a Phillips Gemini scanner. More sensitive scanners would result in improved 
contrasts and hence a wider range of protocols.  
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Summary 
For certain cancers such as glioma, the ability to examine multiple metabolic factors 
simultaneously could assist in understanding the reasons for local progression despite 
treatment. However, acquiring multiple PET scans is not practical in many clinical 
scenarios, hence the potential utility of dual-tracer PET imaging.  Dual-tracer imaging has 
an impact on signal fidelity, so a trade-off between signal accuracy and clinical logistics 
exists. Even so, substantial scope exists to minimise operational impact while retaining 
sufficient signal fidelity. In the context of imaging hypoxia and tumour metabolism, this 
study has examined the trade-off between these factors. The influence of 18F-FMISO 
stabilisation time, pre-18F-FDOPA scan time and 18F-FMISO dose were examined.  
Analysis showed that 90 minutes post injection the 18F-FMISO signal is sufficiently stable 
for subtraction of the static 18F-FMISO signal to give accurate estimates of the 18F-FDOPA 
signal. The pre-18F-FDOPA scan time should be at least 10 minutes in length, assuming 
scanner sensitivity similar to a Phillips Gemini scanner. As the 18F-FMISO signal is typically 
low and relatively static by the time 18F-FDOPA is injected, the increase in 18F-FDOPA bias 
and variance, and the decrease in 18F-FDOPA contrast relative to noise are not excessive. 
Results obtained from dual-tracer mouse data approximately concur with values generated 
from simulations. Some variation was expected due to differences in dosage, biology and 
scanner sensitivity. Residual dynamics will induce some bias, if a static FMISO signal is 
assumed. The bias depends on the FMISO gradient, which at one hour is relatively low 
hence the positive results reported here. Although the induced bias is low, accounting for 
FMISO gradient in the model has the potential to allow the injection interval to be reduced, 
and will be investigated in future work. 
Substantial flexibility exists when selecting protocols for the purposes of combining 18F-
FMISO and 18F-FDOPA. It is likely that dual-tracer imaging is practical in the clinic for other 
combinations of tracer and in different application areas, especially if techniques such as 
kinetic analysis and the pairing of distinctive isotopes are used. 
While performing dual-tracer imaging using this approach is effective, it is restrictive in the 
sense that it cannot be applied when the dynamics of the first tracer are not static. 
Therefore, it would be useful to extend this methodology for dual-tracer imaging to the 
paradigms where dynamics of the first tracer are not static within the tissue during the entire 
imaging session. This leads to the next chapter of this thesis, where this approach is 
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developed further to include the case where the first tracer has some residual dynamics at 
the injection of the second. 
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Chapter 4 – Extension of static dual-tracer imaging to 
the case where first tracer dynamics are not at 
equilibrium. 
 
Introduction 
In the previous chapter, a framework for imaging two tracers simultaneously was 
developed, where it was assumed that the dynamics of the first tracer is at equilibrium at 
injection of the second. However, this assumption does not hold for all tracer combinations. 
This chapter develops the previous technique to allow pre-validation of static dual-tracer 
PET protocols where the first tracer continues to have linear dynamics during injection of 
the second with the specific case of a 64Cu labelled monoclonal antibody specific to the 
EphA2 receptor tyrosine kinase (64Cu-EphA2, nanomedicine) followed by 18F-FDOPA 
(validation) considered. 64Cu-EphA2 was chosen, as it has been shown to have slow 
uptake kinetics that persist for a number of hours(116). This concept is evaluated using a 
set of synthetic dual-tracer and true dual-tracer preclinical data sets. In addition to 
investigating this technique, there is also interest in whether the antibody based tracer, 
64Cu-EphA2 (EphA2 receptor tyrosine kinase), is taken up in regions of metabolically active 
infiltrating tumour as assessed by 18F-FDOPA uptake. 64Cu-EphA2 was chosen as 
overexpression of the Eph receptor tyrosine kinases (RTKs), specifically EphA2, has been 
shown to occur within glioblastoma (GBM) derived cell lines,(117-119) with EphA2 
overexpression linked with poor patient prognosis.(120, 121) As such, EphA2 is an 
attractive therapeutic target for GBM.(122-125) In addition, the use of a monoclonal 
antibody allows, in principle, the application of the imaging methodology described here to 
any Immunoglobulin G (IgG) based nanomedicine as the pharmacokinetics of IgG 
structures are both slow and broadly similar.(126) 
Materials & Methods 
Radiotracer synthesis 
Chemical reagents were sourced from Sigma Aldrich and were used as received. 1,4,7-
triazacyclononane-1,4,7-triacetic acid was purchased from Macrocylics (Dallas, TX) and 
Amicon centrifugal filters were purchased from Sigma Aldrich.  64CuCl2 was produced by 
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the Department of Medical Technology & Physics and RAPID PET Laboratories, Sir 
Charles Gairdner Hospital, Perth, Western Australia.  64Cu-EphA2 was produced as 
previously described29 18F-FDOPA was produced by Queensland PET, Royal Brisbane and 
Women’s Hospital, Brisbane, Queensland. 
Pre-clinical imaging protocols 
In pre-clinical experiments, each mouse was injected with 64Cu-EphA2 (5-7 MBq) and 18F-
FDOPA (5-7 MBq) via the lateral tail vein. 4 hours post injection, mice were anaesthetised 
and a cannula placed in the lateral tail vein. At 1 and 6 hours following injection, mice were 
positioned on the scanner bed in preparation for scanning.   
For single-tracer imaging, thirty minute acquisitions were performed for both 64Cu-EphA2 
and 18F-FDOPA, with imaging acquired on separate days to prevent cross-contamination. 
For true dual-tracer imaging, 60 minute 64Cu-EphA2 acquisitions were performed, with 18F-
FDOPA injected via the cannula 40 minutes following the start of image acquisition. All PET 
images were reconstructed by a two-dimensional ordered subsets expectation maximum 
(OSEM2D) algorithm with no attenuation or scatter correction. In total five mice were 
imaged. Three mice were imaged twice respectively using 18F-FDOPA and 64Cu-EphA2 on 
separate days, with approximately a 24 hour gap between the scans to prevent cross 
contamination. Two mice were imaged when combining 64Cu-EphA2 and 18F-FDOPA. T1-
weighted MR imaging was also performed for each acquisition. 
Synthetic dual-tracer imaging was performed on the acquired raw single-tracer PET list 
mode data, using the method outlined in the previous chapter. Two aspects were 
investigated by this synthetic dual-tracer method; the length of the PET acquisition before 
injection of the second tracer (pre-18F-FDOPA imaging time, τ) and the voxel activity of 
each tracer. For synthetic dual-tracer imaging, the first frame window, τ, was varied at 1, 5, 
10 and 20 minutes. True dual-tracer datasets were reconstructed unedited. 
Separation of dual-tracer signals 
The signals for 64Cu-EphA2 and 18F-FDOPA, respectively 𝐼𝐸𝑝ℎ𝐴2 and 𝐼𝐹𝐷𝑂𝑃𝐴, are functions 
of time, t, and have decay factors  𝜆1 and 𝜆2. Again the terminology to differentiate between 
the activity of the tracer and the intensity of the signal in a PET frame are C and I 
respectively. In the frames after the injection of 18F-FDOPA they are combined to form a 
dual-tracer signal: 
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 𝐼𝑀𝑢𝑙𝑡𝑖𝑝𝑙𝑒𝑥𝑒𝑑(𝑡) = 𝐼𝐸𝑝ℎ𝐴2(𝑡) ∙ 𝑒
−𝜆1𝑡 + 𝐼𝐹𝐷𝑂𝑃𝐴(𝑡) ∙ 𝑒
−𝜆2𝑡 4-1 
To separate the dual-tracer signals post injection, two methods were used. The first was a 
linear model: 
 𝐼𝐸𝑝ℎ𝐴2(𝑡) = 𝛽 𝑡 + 𝛽𝑜 . 4-2 
The parameters 𝛽 and 𝛽 0 can be estimated by performing linear regression on two or more 
frames prior to injection of 18F-FDOPA. The second method assumes a static signal as 
described in the previous chapter where 𝛽 was set to zero. Decay correction was applied 
during image reconstruction by assuming 64Cu was the sole isotope and then correcting for 
18F decay post-reconstruction during the relevant image frames, after removal of the 64Cu-
EphA2 signal: 
 𝐼𝐹𝐷𝑂𝑃𝐴(𝑡) = (𝐼𝑀𝑢𝑙𝑡𝑖𝑝𝑙𝑒𝑥𝑒𝑑(𝑡) − (𝛽 𝑡 + 𝛽𝑜) ∙ 𝑒
−𝜆1𝑡) ∙ 𝑒𝜆2𝑡 4-3 
Thus, the radioactive decay of the tracers was removed from consideration. Here t=0 is the 
time 18F-FDOPA is injected and t=-T is the time 64Cu-EphA2 is injected. Scanning 
commences prior to injection of 18F-FDOPA at t=-τ. The imaging protocol and separating 
scheme are shown schematically in Figure 4-1. 
 
Figure 4-1 – Schematic diagram of the imaging protocol, showing injection of 64Cu-EphA2 at t=-T. Scanning is initiated at 
t=- τ and at t=0 18F-FDOPA is injected. The activity of the tracers are represented by C and the intensity of the Pet signal 
for a given PET frame is represented by I. At least two PET frames are required between t=- τ and t=0, to calculate the 
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linear fit, 𝛽 𝑡 + 𝛽𝑜, which is subtracted from 𝐼𝑀𝑢𝑙𝑡𝑖𝑝𝑙𝑒𝑥𝑒𝑑 to obtain 𝐼𝐹𝐷𝑂𝑃𝐴. The effect of the two decay factors 𝜆1 and 𝜆2is no 
shown. 
Image Analysis: Dual-Tracer signal error 
For the three mice imaged on separate days, a map of 18F-FDOPA error, ε, was calculated 
for each voxel in the image volume using the single-tracer 18F-FDOPA data, 𝐼𝐹𝐷𝑂𝑃𝐴(𝑡), as 
the signal of reference:  
 
𝜀 =
|𝐼𝐹𝐷𝑂𝑃𝐴(𝑡) − 𝐼𝐹𝐷𝑂𝑃𝐴(𝑡)|
𝐼𝐹𝐷𝑂𝑃𝐴(𝑡)
 4-4 
where, as before, 𝐼𝐹𝐷𝑂𝑃𝐴(𝑡) denotes the 
18F-FDOPA signal obtained from dual-tracer 
imaging. Following this, cumulative error histograms were generated for the whole mouse 
volume for each separation method over the investigated range of τ and tracer activity.  
Image Analysis: 64Cu-EphA2-18F-FDOPA spatial correlation 
To investigate 64Cu-EphA2 as a potential tracer, linear regressions across 18F-FDOPA and 
64Cu-EphA2 voxel activities were performed individually for each of the five subjects, with 
the Pearson’s correlation coefficients calculated to investigate the relationship between the 
two tracers. Regions of interest (ROIs) were drawn for active tumour using an acquired 
gadolinium contrast MR image. For the three mice imaged on separate days, the 64Cu-
EphA2 and 18F-FDOPA images were reconstructed individually and rigidly registered using 
MILXView milxAliBaba.(127) To enable better inter-subject comparison, PET intensities 
were normalised to the cerebellum to generate tumour-to-normal ratio (T/N) maps.  
Statistical analysis 
Investigations were performed to determine if dual-tracer imaging produces statistically 
different results to that of independent imaging. Pairwise t-tests were performed to 
determine the similarity in relationship between the two tracers across all five mice. The 
pairwise testing was used to establish the influence of dual-tracer imaging, if any. 
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Results 
Dual-Tracer signal separation: Static vs linear models 
Synthetic dual-tracer datasets were combined by interleaving the list mode data of each 
tracer acquired on separate days. The combined datasets were simulated according to the 
protocol outlined in Figure 4-1 with variable lengths of τ. Figure 4-2 and Figure 4-3 show 
the fidelity of signal separation using both static and linear separation methods for 
investigated values of τ. Figure 4-2 shows images of a specific anatomical slice for a 
selected mouse imaged six-hours post injection of 64Cu-EphA2. It can be qualitatively seen 
that by increasing τ, 64Cu-EphA2 signal fidelity, signal separation and subsequent 
extraction of the 18F-FDOPA activity are all improved. 
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Figure 4-2 – Images of an anatomic slice for one of the synthetically combined mice, imaged six hours post injection of 
64Cu-EphA2. The tumour is shown in a T2 weighted MRI (a) for reference. Independently obtained thirty minute 64Cu-EphA2 
(b) and 18F-FDOPA (c) scans were synthetically combined (d) using the list mode data to simulate τ values of 1, 5, 10 and 
20 minutes. Reconstruction and decay correction was performed using the original scanner software. Using the 64Cu-
EphA2 frame (e,h,m,r), 64Cu-EphA2 activity was subtracted from the dual-tracer frame to recover the 18F-FDOPA activity 
by means of the static method (f,i,n,s) and the linear method (k,p,u). Error in the estimated 18F-FDOPA activity, expressed 
as a percentage of the true signal, is shown for both the static method (g,j,o,t) and linear method (l,q,v). 
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Figure 4-3 – Quantitative results from the three synthetically combined mice imaged at one hour (a) and six hours (b) post 
injection of 64Cu-EphA2. Figures are cumulative sums of 18F-FDOPA error across the mouse volume and averaged across 
the three mice. The larger the tail of the curve, the greater the error across the volume. For lower values of τ (1-10 minutes) 
the original static method outperforms the extended linear method. However for a τ value of 20 minutes, the linear method 
outperforms the static method. 
 
These results are displayed quantitatively in Figure 4-3 for both one hour and six hours 
post injection of 64Cu-EphA2, averaged across the three mice. Cumulative distributions of 
extracted 18F-FDOPA signal error are plotted for increasing τ. Again, it can be seen that by 
increasing τ, the ability to separate the dual-tracer signals improves. In addition, it can be 
seen that signal separation improves when the linear method for signal separation is used 
for long values of τ.  
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Figure 4-4 – Joint histograms (frequency plots) of (a) error versus 18F-FDOPA and (b) 64Cu-EphA2 activity for the mouse 
displayed in Figure 4-2, showing the relationship between the amount of activity and the resulting error for 18F-FDOPA. For 
64Cu-EphA2 the relationship is less prominent. 
Further experiments were performed to investigate which voxels cause the highest errors 
in signal separation. Figure 4-4a shows the error in 18F-FDOPA versus the 18F-FDOPA 
activity. It can be seen that areas of high error are likely to occur in voxels where 18F-
FDOPA activity is low. In addition, Figure 4-4b shows the error in extracted 18F-FDOPA 
versus 64Cu-EphA2 activity. While a relationship also appears to exist here, it is less 
pronounced, suggesting it has less of an effect on fidelity of the extracted signal.  
Using Dual-Tracer PET to validate potential nanomedicines 
To demonstrate that combining a potential nanomedicine and a validation tool is logistically 
possible, two real dual-tracer experiments were performed. An anatomical slice of a true 
dua-tracer mouse is shown in Figure 4-5. Here, the contrast enhanced MRI shows the 
location of the tumour, with 64Cu-EphA2 and extracted 18F-FDOPA images showing 
significant uptake in this region.  
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Figure 4-5 – Anatomical slice of the real dual-tracer mouse. The mouse was injected with 64Cu-EphA2 at time zero. After 
240 minutes post injection, scanning was initiated. After 280 minutes post injection, the mouse was injected with 18F-
FDOPA and scanning continued for an additional 20 minutes. The data was reconstructed using the original scanning 
software, correcting for 64Cu-EphA2 decay. The activity of 64Cu-EphA2 (b) was subtracted linearly from the dual-tracer 
frame (c) to extract the 18F-FDOPA activity (d). The tumour is shown in the MRI (a) for reference. ROIs defined on the MRI 
are shown in (e) with the corresponding mean activities for each ROI. Activities in (e) are 64Cu-EphA2 only for the first 40 
minutes (240 – 280 minutes post injection of 64Cu-EphA2) and 64Cu-EphA2 + 18F-FDOPA for the remaining 20 minutes 
(280 – 300 minutes post injection of 64Cu-EphA2)  
Figure 4-6 shows the voxel-wise correlation between 64Cu-EphA2 and 18F-FDOPA for each 
of the five mice (3 single-tracer and 2 dual-tracer). Tumour and normal tissue Pearson’s 
correlation coefficients, r2, are shown above each plot. It can be seen that there is a clear 
correlation between tracer activities in four of the five mice. 
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Figure 4-6 – Voxel-wise correlation between 18F-FDOPA and 64Cu-EphA2 uptake in the five mice imaged. The voxel-wise 
Pearson’s correlation coefficient r2 is shown above each plot.  
 
 
 
Statistical validation of the Dual-Tracer method 
Table 4-1 shows p-values for the pairwise t-test performed for each pair of mice. Mice #1-
#3 were single-tracer mice where imaging was performed on separate days. Mice #4 and 
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#5 were the dual-tracer mice. Low t-statistics with associated high p-values indicate the 
slopes of regression, i.e., the correlation of the tracers are similar between the two mice 
tested. It can be seen from the table that only one mouse, mouse #3, has a significantly 
different slope from the others.  
 
Table 4-1 – t-values, standard error and p-values for the pairwise t-test performed for each pair of mice. Mice #1-#3 were 
single-tracer mice where imaging was performed on separate days. Mice #4 and #5 were dual-tracer mice. 
Mouse #1 
(Registered) 
#2 
(Registered) 
#3 
(Registered) 
#4 (Dual-
Tracer) 
#5 (Dual-
Tracer) 
Slope 2.41 3.66 2.36 2.41 2.34 
Standard Error 0.14 0.16 0.24 0.21 0.11 
R2 0.57 0.57 0.29 0.38 0.35 
N 220 420 237 217 563 
#1 (Registered)   5.88 
(p<10-6) 
0.18 
(p=0.85) 
0 
(p=1.00) 
0.39 
(p=0.69) 
#2 (Registered) 
 
  4.51 
(p<10-6) 
4.73 
(p<10-6) 
6.80 
(p<10-6) 
#3 (Registered) 
  
  0.16 
(p=0.87) 
0.08 
(p=0.94) 
#4 (Dual-
Tracer) 
    
0.30 
(p=0.76) 
#5 (Dual-
Tracer) 
     
 
 
 
Discussion 
The error associated with dual-tracer image acquisition and subsequent image extraction 
was investigated by synthetically creating dual-tracer datasets from images acquired on 
two separate days. In this way, single-tracer data can be used to produce measures of 
signal fidelity and allows experiments to be performed that can be used to pre-validate 
dual-tracer imaging protocols. Here, the time prior to injection of 18F-FDOPA, τ, and the 
concentration (activity) of each tracer in an imaging voxel were investigated for their effect 
on signal fidelity. 
In the real-world experiments no ground truth is available. At best, it can be assumed that 
the signal is the best estimate of PET activity that can be obtained with the hardware, albeit 
with error bounds that can be established. Hence experiments attempted to estimate bias 
with respect to the non-multiplexed PET reconstructions (i.e. not the ground-truth) and that 
the variance in the signal estimates did not increase materially. Also given the manner in 
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which PET scanners are read, where clinicians identify hyper-intensities within a noisy 
background sometimes in comparison to contralateral regions, results were usually 
reported in terms of contrast in units of signal standard deviation (which implicitly accounts 
for noise). 
It can be seen from Figure 4-2 and Figure 4-3 that the scanning time prior to injection of 
18F-FDOPA (τ) must be sufficiently long to adequately estimate the 64Cu-EphA2 signal. If τ 
is too short, linear regression will be excessively erroneous, leading to a poor estimation of 
the 64Cu-EphA2 signal and a subsequently poor extraction of the 18F-FDOPA activity. In 
addition, qualitative and quantitative measures calculated from a 64Cu-EphA2 acquisition 
that is too short will be inaccurate. However, overcompensating will increase the scanning 
time unnecessarily. It can be seen that as the scanning interval is lengthened from one 
minute to twenty minutes, the fidelity of both the 64Cu-EphA2 and 18F-FDOPA signals 
increases. Figure 4-3 provides quantitative results that corroborate this, showing that, as 
the pre-18F-FDOPA scanning interval is lengthened, the quality of the extracted 18F-FDOPA 
signal increases. Furthermore, as can be seen in all three figures that the improvement in 
the signal fidelity between 10 and 20 minutes is not significant, suggesting a scanning 
interval of 10 minutes may suffice for most cases, and lengthening scan time beyond this 
is unnecessary. 
In addition, it can be seen that the time between injection of 64Cu-EphA2 and 
commencement of scanning has a model-dependent effect on the fidelity of the extracted 
signal. For this study, post injection times of one and six hours were chosen for 64Cu-
EphA2. For a τ value of 20 minutes, the gain in signal fidelity when using linear regression 
over the static approach is greater for a post 64Cu-EphA2 injection time of 1 hour compared 
to 6 hours. This is likely due to the changing uptake dynamics of the antibody into the 
tumour volume. It has previously been shown that uptake of 64Cu-EphA2 into the tumour 
reaches a state of equilibrium approximately 6 hours post injection and so it follows that 
use of a linear model at six hours does not offer significant advantage over a simpler static 
model. Extending the FDOPA scan or including the period with faster uptake would likely 
increase the advantage of using a linear model (if τ is sufficient, and the linear assumption 
holds). The increase in performance of the linear model at shorter times post injection of 
64Cu-EphA2 becomes pertinent when considering application of this framework to other, 
non-antibody based, nanomedicines. Potential nanomedicines based upon peptide 
systems, small proteins or synthetic polymers may have different pharmacokinetics to a 
monoclonal antibody and may not exhibit regions of dynamics that can be modelled as 
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static. As such, the application and validation of a linear model to describe the dynamics of 
the first tracer and its use in separating dual-tracer PET signals significantly broadens the 
applicability of this methodology. 
Finally, it can be seen (Figure 4-4) that the injected dose of each tracer has an effect on 
the fidelity of the extracted signal, due to the Poisson noise of PET. If the injected activity 
is too low, the detected activity will also be low. This will firstly result in a low signal-to-noise 
ratio, lowering the quality of the acquired images of the first tracer. In addition, it can be 
seen in Figure 4-4 that low activity also negatively affects the performance of signal 
separation. Figure 4-4 shows the extracted 18F-FDOPA signal error plotted against both 
the 18F-FDOPA activity (Figure 4-4a) and the 64Cu-EphA2 activity (Figure 4-4b). If the 18F-
FDOPA activity is too low, the error from estimation of the 64Cu-EphA2 signal will be 
significant in comparison, leading to an erroneous signal extraction (Figure 4-4a). In 
addition, a low 64Cu-EphA2 signal-to-noise ratio will also negatively affect the signal 
separation, as it introduces more uncertainty into the regression’s output variables (Figure 
4-4b). While the 64Cu-EphA2 appears to be less influential on signal separation, a trend is 
still obvious. Therefore, it appears that increasing the dose of both tracers improves the 
fidelity of the separated signals. However, the dose of 18F-FDOPA should be larger than 
the dose of 64Cu-EphA2 to minimize the effect of any error in 64Cu-EphA2 signal estimation.  
A potential issue of dual-tracer PET imaging is the logistics of synthesising both radiotracers 
on the same day. This issue is limited in this work, as the 64Cu isotope, which as a half-life 
of 12.7 hours, was able to be synthesised offsite and transported the day before imaging. 
The radiolabelling and characterisation of 64Cu-EphA2 was performed in parallel to the 
synthesis of 18F-FDOPA so that both radiotracers were available at the time of imaging. 
To fully validate the methodology, statistical comparisons were drawn between synthetic 
dual-tracer datasets and true dual-tracer datasets. A pairwise t-test was performed for each 
pair of mice, the results of which are shown in Table 4-1. This test identifies which 
regression slopes were significantly different, i.e., which mice suggested a different 
relationship between the two tracers. As can be seen, the only mouse that was significantly 
different from the others was #2, a single-tracer mouse. After reviewing the data, it appears 
that a possible explanation of this is the injection of 64Cu-EphA2 into the mouse, in particular 
the cannula itself. There was significant activity surrounding the cannula, suggesting that it 
was displaced during injection, preventing the tracer from entering the tail vein effectively. 
This mouse was only included in the final results for completeness.  This suggests that 
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performing dual-tracer PET imaging does not place a significant bias on the results, and 
that either method should give viable information when comparing the spatial distribution 
of two tracers. 
Finally, this framework could readily be extended to other paradigms, where the residual 
dynamics cannot be represented by a static or linear model. The uptake dynamics of 64Cu-
EphA2 is relatively slow due to the large size of the 64Cu-EphA2 molecule, decreasing the 
permeability. However, if a potential theranostic with a higher permeability is developed, 
the uptake dynamics may increase significantly. If this were the case, an exponential model 
may be more fitting for separating any dual-tracer signals. Here, modification of 4-2 can be 
performed to include the exponential term desired, extending this framework into an 
exponential paradigm.  
Summary 
In this chapter, an extension to the previous technique for pre-validating protocols for dual-
tracer imaging was presented. Here, it is assumed that the rate of change of activity for the 
first tracer was constant at the injection of the second. This technique was evaluated on a 
set of spatially registered images of a potential nanomedicine and a diagnostic marker of 
disease progression. Furthermore, this methodology should be applicable to any IgG type 
structure or nanomedicine of similar pharmacokinetic behaviour. Finally, it was shown that 
by using more complex models to describe the dynamics of the first tracer, it may be 
possible to apply this methodology to nanomedicines with more complex pharmacokinetics 
that do not reach steady state for some time.  
Coupled with the methodology presented in chapter 3, a framework is now available for 
performing dual-tracer imaging when the dynamics of the first tracer is static or linear. 
However, for a large number of tracers, this is not applicable as the residual dynamics are 
non-linear.  Thus, to fully investigate and provide tools for effective dual-tracer imaging, the 
case of imaging two tracers with rapid dynamics must be investigated.
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Chapter 5 - Performing dual tracer PET imaging in the 
general case by extending Basis Pursuit 
Introduction 
Previous work in this thesis is limited to cases where the dynamics of the first tracer are 
known a priori as either static or linear. For many cases, this is not possible. This chapter 
consists of the paper “Performing dual tracer PET imaging in the general case by extending 
Basis Pursuit” resubmitted with requested major revisions, and proposes a technique that 
uses the basis pursuit formulation (128) to consider the general case that represents all 
biology and PET radio-isotopes, allowing for pre-validation of scanning protocols irrelevant 
of the tracer combination used. Basis pursuit allows model complexity to be defined by the 
data and its formulation can be naturally extended to separating pairs of dynamic signals 
with an injection interval, T. The approach is applied by optimising the injection delay and 
relative injected activity for the general case where residual dynamics from a first tracer 
exist during injection of a second. Validation of the approach is performed by examining 
the statistics of the residual and parameters of the fitted curves within tissues. 
Materials & Methods 
The Basis Pursuit Technique 
The temporal evolution of a tracer within the body can be modelled using time activity 
curves (TACs), which can be used to extract kinetic parameters. Kinetic analysis is often 
formulated as a numerical solution of a set of ordinary differential equations, yielding a set 
of kinetic parameters. Non-linear regression is typically used for this purpose, however this 
requires the prior selection of a compartment model. As described by Gunn et al. (128), an 
alternative representation is to describe the tissue as a linear combination of input response 
functions, shown in 5-1. 
 
𝐶(𝑡) =  𝑉𝑏𝐶𝑏 + (1 − 𝑉𝑏)∑𝜙𝑖𝑒
−𝜃𝑖𝑡
𝑛
𝑖=1
⨂𝐶𝑝(𝑡) 5-1 
where C is the activity concentration within the tissue at time t. Vb and Cb are the blood 
volume fraction and blood activity concentration, respectively. ⨂ is the convolution 
operator, φ and Ѳ are the weight and rate of decay defining each of the n terms. The 
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number of terms, n, can be left unfixed, removing the requirement for a prior selection of 
the model. Extending 5-1 to the dual-tracer case: 
 𝐶(𝑡) = 𝐶𝛼(𝑡) + 𝐶𝛽(𝑡 + 𝑇) 5-2 
 
= 𝑉𝑏𝛼𝐶𝑏𝛼 + (1 − 𝑉𝑏𝛼)∑𝜙𝑖𝑒
−𝜃𝑖𝑡
𝑛𝛼
𝑖=1
⨂𝐶𝑝𝛼(𝑡)  + 𝑉𝑏𝛽𝐶𝑏𝛽 + (1 − 𝑉𝑏𝛽)∑𝜙𝑖𝑒
−𝜃𝑖(𝑡+𝑇)
𝑛𝛽
𝑖=1
⨂𝐶𝑝𝛽(𝑡 − 𝑇)   
where the subscript 𝛼 is used for the first tracer, and 𝛽 for the second. The injection interval 
between the tracers is explicitly symbolised by T. A solution to 5-2 can be found for a 
sample tissue using a dictionary for each tracer. The dictionary, Ѱ, is a matrix of kinetic 
basis functions, each of which is calculated as:  
 
 
𝜓𝑖(𝑡) =  ∫ 𝑒
−𝜃𝑖(𝑡−𝜏)𝐶𝑝(𝜏)𝑑τ
𝑡
0
 
𝜓0(𝑡) =  𝐶𝑝(𝑡) 
 
5-3 
where 𝜃𝑖 is varied over a physiologically plausible range. Cp is the plasma input function 
that represents the concentration time course of the tracer in the plasma, determined prior 
to the generation of the dictionary. The first basis function 𝜓0is set to Cp to allow estimation 
of the arterial activity in the sample tissue. 
Basis functions are widely used for model fitting because they allow the linear and non-
linear parameters in model to be solved independently, accelerating optimisation and 
improving robustness, e.g. the BAFPIC (Basis Functions from Plasma Input 
Compartments) approach proposed by Hong et al. (16), with extensions to ensure 
distinguishability of the two compartments by Kadrmas et al. (17) and formulations tailored 
to the GPU (18). However, basis pursuit adds the use of L1-regularisation (described in the 
next section) during optimisation to enforce sparsity which allows the choice in the structure 
of the compartment model to be dictated by the data on a per-voxel basis. This provides 
an important advantage for separating signals in dual tracer images containing multiple 
tissue types with uptake patterns that are likely heterogeneous and when it is not yet clear 
whether a particular tracer (with lower uptake) is even distinguishable. 
  
58 
Application of Basis Pursuit to Dual-Tracer Imaging 
The resulting dictionary for each tracer can be described using 5-4 
 
𝛙𝜶 = [
𝜓𝛼01 ⋯ 𝜓𝛼𝑁𝛼1
⋮ ⋱ ⋮
𝜓𝛼0𝐹 ⋯ 𝜓𝛼𝑁𝛼𝐹
] ,𝛙𝜷 = [
𝜓𝛽01 ⋯ 𝜓𝛽𝑁𝛽1
⋮ ⋱ ⋮
𝜓𝛽0𝐹 ⋯ 𝜓𝛽𝑁𝛽𝐹
], 5-4 
where N is the number of dictionary elements and F is the number of image frames. For 
this study, a value of 30 was chosen for N, as at this resolution linear interpolation has been 
shown to provide a good approximation of parameters while being computationally efficient 
(128). The two dictionaries are concatenated with the second dictionary’s values prior to its 
injection time set to zero 
 
𝛙 = [
𝜓𝛼01 ⋯ 𝜓𝛼𝑁𝛼1
⋮ ⋱ ⋮
𝜓𝛼0𝐹 ⋯ 𝜓𝛼𝑁𝛼𝐹
  
𝜓𝛽01 ⋯ 𝜓𝛽𝑁𝛽1
⋮ ⋱ ⋮
𝜓𝛽0𝐹 ⋯ 𝜓𝛽𝑁𝛽𝐹
] 5-5 
 
An example dictionary set is shown in Figure 5-1. A sparse linear combination of the 
dictionary elements can be computed to describe the data using the Basis pursuit as 
originally proposed in (128). Sparse in this case implies most of the coefficients associated 
with dictionary elements, 𝐲 = [𝑦1…𝑦𝐹]
𝑇, are zero. 
 
Figure 5-1  Example of a dictionary for two tracers with a given injection delay. The first tracer is shown in blue and the 
second in red. The final dictionary is a linear combination of the two. 
Sparsity is achieved by utilisation of L1 regularisation, modulated by the regularisation 
parameter, μ, within a quadratic programing framework to enforce positivity in the 
coefficients, 𝛟: 
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 𝑚𝑖𝑛
𝜙
1
2
‖𝐖
1
2(𝐲 −  𝛙𝛟)‖
2
2
+ μ‖𝛟‖1 5-6 
The regularisation parameter μ is set globally for the image volume using leave one out 
cross-validation (LOOCV) as per (128). Typically μ is scalar, but to impose prior knowledge 
about the expected relative activities of the two tracers a vector can be used; for example, 
to account for a large relative difference in injected activities. In the following experiments, 
the standard scalar definition of μ is used. Once Basis Pursuit is performed, the identity of 
the dictionary elements with non-zero elements allows the individual tracers to be 
separated. From the calculated coefficients, key macroscopic parameters can be 
calculated. For this study, two parameters were investigated, based on the tracer 
reversibility of the tissue being investigated: 
Volume of distribution (VT), the ratio of the tracer concentration in tissue target to that in 
plasma at equilibrium, calculated as ∑
𝜙𝑖
𝜃𝑖
  (129). VT is appropriate for reversible kinetics, 
where the tracer is both taken up and excreted by the tissue. 
Irreversible uptake rate (KI), the rate of tracer that is irreversibly bound in the tissue, 
calculated as 𝜙𝑛 (129). KI is appropriate for irreversible kinetics, where the tracer is taken 
up but not excreted by the target tissue.  
It’s important to note that the choice of VT and KI is irrelevant with regards to the 
methodology, as the algorithm performs in the general case and can be implemented 
regardless of the reversibility of the tracers chosen. In the following experiments available 
18F-FDOPA and 18F-FDG data were utilised. 
Quantifying Error 
In the single tracer case, the error in fit can be attributed to the random noise in the system, 
𝜀𝑁𝑜𝑖𝑠𝑒, controlled by the injected tracer activity and the geometry of the scanner such that: 
 𝐶𝑁𝑜𝑖𝑠𝑦(𝑡) = 𝐶(𝑡) + 𝜀𝑁𝑜𝑖𝑠𝑒 5-7 
The signal noise also acts to induce the standard deviation in any estimates in derived 
parameters, 𝜎𝑛𝑜𝑖𝑠𝑒
(𝑝,𝑖)
, for either tracer, where p indicates the parameter of interest and i the 
tracer. When performing dual-tracer imaging, the additive noise will act to increase the 
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standard deviation by a certain amount, 𝜎𝑚𝑢𝑙𝑡𝑖𝑝𝑙𝑒𝑥
(𝑝,𝑖)
, as  may the linear dependence of the 
two tracer profiles if activity from one tracer is incorrectly attributed to the other. The latter 
can also act to induce a bias in the estimate, 𝜀𝑚𝑢𝑙𝑡𝑖𝑝𝑙𝑒𝑥
(𝑝,𝑖)
.  
In the ideal dual tracer case, 𝜎𝑚𝑢𝑙𝑡𝑖𝑝𝑙𝑒𝑥
(𝑝,𝑖)
 and 𝜀𝑚𝑢𝑙𝑡𝑖𝑝𝑙𝑒𝑥
(𝑝,𝑖)
 approach zero, but in practice there 
will be some finite fraction of 𝜎𝑛𝑜𝑖𝑠𝑒
(𝑝,𝑖)
, which the designed protocol will aim to minimise. 
Investigating the feasibility of imaging protocols 
Given this formulation, it is therefore possible to estimate the amount of error expected 
when performing dual-tracer imaging under certain scanning protocols using a simulation 
based approach (Figure 5-2). This approach is performed in two steps: Generation of 
single-tracer data (Figure 5-2.1) and a feasibility study of dual-tracer protocols (Figure 
5-2.2).  
Using available single-tracer scans (Figure 5-2.1a) pharmacokinetic fits can be performed, 
extracting kinetic parameters for specific tissues of interest (Figure 5-2.1b). Single and 
Dual-Tracer pharmacokinetic time activity curves can then be synthetically generated 
(Figure 5-2.2a). 1000 instances of randomly generated noise are added to each simulation 
as per 3-6 and combined to generate synthetically combined dual-tracer curves (Figure 
5-2.2b). Single- and dual-tracer simulations are then processed using the basis pursuit 
method to extract pharmacokinetic parameters (Figure 5-2.2c). The fitted parameters are 
compared to examine the increase in variance due to dual-tracer imaging (Figure 5-2.2d).  
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Figure 5-2  Flowchart for feasibility study of dual-tracer imaging protocols. It is convenient to consider the approach in two 
steps: Generation of single-tracer data (Step 1) and feasibility study of dual-tracer protocols (Step 2). First, a single-tracer 
imaging sessions must be performed if single-tracer data is not currently available for each tracer (a). From this, kinetic 
analysis is performed to determine the pharmacokinetic parameters associated with the tissues to be investigated (b). The 
second step allows a feasibility study of dual-tracer imaging protocols. First, single-tracer pharmacokinetic curves are 
generated using known kinetic parameters, generated from single tracer images acquired previously (a). These curves are 
then sampled 1000 times for noise as per 3-6 and combined to generate synthetically combined dual-tracer curves (b). 
Single- and dual-tracer simulations are then processed using the basis pursuit method to extract pharmacokinetic 
parameters (c). Single- and dual-tracer parameters can then be compared to assess if the scanning protocol is acceptable 
(d). 
 
Physical phantom experiment 
To demonstrate the principle of dual-tracer imaging, an experiment was performed to 
evaluate the separation process with real data while still retaining the original single-tracer 
signals. In the real-world experiments no ground truth is available. At best, it can be 
assumed that the signal is the best estimate of PET activity that can be obtained with the 
hardware, albeit with error bounds that can be established. Hence experiments attempted 
to estimate bias with respect to the non-dual-trracer PET reconstructions (i.e. not the 
ground-truth) and that the variance in the signal estimates did not increase materially. Also 
given the manner in which PET scanners are read, where clinicians identify hyper-
intensities within a noisy background sometimes in comparison to contralateral regions, 
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results were usually reported in terms of contrast in units of signal standard deviation (which 
implicitly accounts for noise). To accomplish this, a physical phantom experiment using 
four Slide-A-Lyzer dialysis cassettes (https://www.thermofisher.com/) in conjunction with a 
sealed partitioned container was used. The dialysis cassettes were used to mimic uptake 
of the tracer from the blood into the cells (Figure 5-3a). Here, each partition represented a 
cell and each cassette represented the plasma. Two cassettes had a 3.5K molecular weight 
cut off (Tracer 1) and the other two had a 7K molecular weight cut off (Tracer 2). The lower 
the cut off, the lower the permeability and therefore the slower the dynamics. As per Figure 
5-3a, a cassette was placed in each of partition one and two to represent single tracer 
injections. These compartments acted as the control for the experiment. In the third 
partition, one of each of the cassettes were inserted to represent dual-tracer imaging. Each 
cassette was prefilled with 1.5mL of distilled water. The scanning apparatus was placed 
into a Siemens Inveon pre-clinical PET/CT Scanner and scanning was initiated. The two 
“tracer 1” cassettes were immediately injected with 18F-FDG, with the remaining two 
cassettes injected after 20 minutes to represent a 20 minute injection delay (Figure 5-3b). 
All cassettes were injected with 0.5mL of 18F-FDG tracer. The specific injected activities for 
each cassette are shown in Table 5-1, with activities from each container normalised for 
differing injection doses.  
 
Figure 5-3  Experimental set up of the phantom study. A container was segmented into three separate and isolated 
partitions and filled with water (a). Cassettes were placed in each partition – one in each of partition one and two to 
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represent single-tracer activities and two in partition three to represent dual-tracer. Cassettes for tracer one were injected 
at zero minutes and cassettes for tracer two were injected at 20 minutes (b).  
 
 
Table 5-1  Injected doses for each of the four cassettes used in the phantom experiment. 
Cassette Injected Dose 
Single Tracer 1 2.16Mbq 
Single Tracer 2 2.18Mbq 
Dual Tracer 1 2.22Mbq 
Dual Tracer 2 2.08Mbq 
Segmentations of the bag (acting as the “plasma” compartment in a one compartment 
model) and the remainder of the partition (acting as an extra-vascular space) were obtained 
from the CT. The entire volume within each partition consisting of the bag and the 
remainder of the partition substitutes as a single voxel within an image. 
The time course of concentration within the bags decays more slowly than is typical of 
blood activity concentrations in PET images, but increases the linear dependence of the 
blood activity concentration and the summed TAC. Hence in this aspect the experiment is 
conservative, as it increases the linear dependence of the two signals as well. 
To validate the proposed dual-tracer approach, single-tracer compartments were fitted 
using the basis pursuit method (Figure 5-2.1). Simulations were then performed to simulate 
and test the feasibility of the dual-tracer protocol used (Figure 5-2.2). Dual-tracer activity 
was separated to obtain the single-tracer kinetic parameters and the normalised activities 
and parameters for each were compared to validate both the experiment and the separation 
method. 
 
Experiment using synthetic combination of real data to simulate dual-tracer 
imaging 
A further demonstration of the process outlined in Fig. 2 was made using a test-retest 
experiment with (real) images of a NOD/SCID mouse bearing a patient derived (WK1 cell 
line) glioma cranial xenograph in the right striatum(116). All animal experiments were 
approved by The University of Queensland Animal Ethics Committee and conformed to the 
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guidelines of the Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes.  
A 30 minute 18F-FDOPA dynamic image was acquired with an injected dose of 4.84 MBq 
(Figure 5-2.1a). From this data, basis pursuit was performed to extract the pharmacokinetic 
time activity curves and kinetic parameters for each tissue voxel (Figure 5-2.1b, Figure 
5-2.2a). Simulations were performed to generate 1000 noisy single- and dual-tracer time 
activity curves for each voxel (Figure 5-2.2b). Finally, basis pursuit was once again used to 
obtain kinetic parameters from both single- and dual-tracer curves (Figure 5-2.2c) with 
kinetic parameters compared (Figure 5-2.2b) for various injection delays.  
To remain as realistic as possible in the experiment, the original single-tracer image was 
interleaved with itself in list-mode form to create a synthetic dual-tracer experiment where 
the mouse was injected with the same tracer twice, with injection intervals set to the same 
as above. The purpose of interleaving the list-mode data was to eliminate the potential 
positive bias (if any) of combining the post-reconstruction data, and to remove the limitation 
from chapter three where biological information could not be obtained. Furthermore, in a 
perfect situation, kinetic information obtained for both injections should be identical, 
allowing visual inspection on the effect of tracer ordering on the results. This “list-mode” 
dual-tracer image was separated using the basis pursuit approach, with the variance in VT 
calculated and compared to the above to ensure the process set out in Figure 5-2 is 
effective. 
True dual-tracer imaging experiment 
Finally, the basis pursuit method for separating dual-tracer signals was demonstrated using 
a single dual-tracer mouse injected with18F-FDG and 18F-FDOPA. This was a proof of 
concept experiment performed on a NOD/SCID mouse bearing a patient derived (WK1) 
glioma cranial xenograph in the right striatum. A sixty minute acquisition was performed 
where the mouse was injected with 2.75 MBq of 18F-FDG at t=0. Using the feasibility from 
the previous experiment, a delay of 20 minutes was selected, after which 1.73 MBq of 18F-
FDOPA was injected and scanning continued for another 40 minutes. The reconstructed 
dataset was separated using the proposed basis pursuit method to extract the macroscopic 
parameters VT for 18F-FDOPA and KI for 18F-FDG, with recovered parameters compared 
to acquired single-tracer data (used in previous experiment) and the literature (130, 131) 
for manually delineated ROIs of brain tumour and cortical tissue. While only a single mouse 
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was imaged, the large number of intra-subject voxels allows voxel-wise investigations to 
be performed.  
Results 
Physical phantom experiment 
In a typical image with vascular regions within the field of view that is distinct from the tissue 
being investigated, a blood activity concentration can be extracted. In this experiment the 
segmented bags were used for this purpose.  
Initially the “blood activity concentration” of each bag type were compared to ensure 
approximately equal blood activity concentration for subsequent validation. From Figure 
5-4, it is clear that the diffusion rates for each of the two tracers is very similar, suggesting 
that the experimental process was successful, with equal tracer concentrations delivered 
to the cell compartments for each tracer.  
Next fits were performed to simulate fitting entire TACs (for which the sum of compartments 
is visible). Figure 5-5 shows the single-tracer (maroon & orange) and dual-tracer (red) 
activities for the delineated cell compartments. From this data, single-tracer (green & blue) 
and dual-tracer (cyan & brown) fits were performed. From the figure, it can be seen that 
the single-tracer and separated dual-tracer fits are in agreement, suggesting that the 
single-tracer activities can be recovered from dual-tracer imaging. 
Figure 5-4 and Figure 5-5 show that a comparison between the single-tracer and dual-
tracer compartments is possible, allowing a controlled analysis to be performed on the data. 
Figure 5-6 shows a comparison between the variance in KI calculated via simulations of 
TACs generated from single-tracer compartments (box plots; Figure 5-2.2b) and the KI 
calculated from the dual-tracer compartment (asterisks). Results show that KI as calculated 
from dual-tracer compartments lies within the range of values of KI calculated from 
simulations generated from single-tracer compartments (Figure 5-2.2d). 
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Figure 5-4  Diffusion of 18F-FDG from the blood compartment into the cell compartment. Here it can be seen that the 
diffusion rates for each of the two tracers (control & dual) is very similar, suggesting that the experimental process was 
successful, with equal tracer concentrations delivered to the cell compartments for each tracer.  
 
 
Figure 5-5  Activities and kinetic fits for each of the cell compartments. Single-tracer (maroon & orange) and dual-tracer 
(red) activities are shown as measured by the scanner. From this data, single-tracer (green & blue) and dual-tracer (cyan 
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& brown) fits were performed. Here, it can be seen that the single-tracer and separated dual-tracer fits are in agreement, 
suggesting that the single-tracer activities can be recovered from dual-tracer imaging. 
 
Figure 5-6  Comparison of KI as measured from the dual-tracer compartment (star) with the variance of KI as calculated 
from the single-tracer simulations.  
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Synthetically combination of real data to simulate dual-tracer imaging 
Two investigations were performed using pre-clinical data and the macroscopic parameter 
VT for two purposes. Firstly the experiment was used to evaluate the ability to predict the 
variance encountered when performing dual-tracer imaging on real data using the 
methodology set out in Figure 5-2. Secondly the experiment was used to evaluate the 
increase in bias and variance in VT when performing dual-tracer imaging over single-tracer 
imaging and as a function of injection delay. 
Figure 5-7 shows how the amount of bias introduced to VT when performing dual tracer 
imaging over single tracer can be predicted for increasing delay. Plots are shown in groups 
of four for each injection delay investigated, with plots shown in red reflecting tumour tissue 
and plots in green depicting normal tissue. The left plot for each colour is from simulated 
data, used to predict the bias in the real data (shown as the right plot for each colour). The 
distribution of VT calculated from real data closely resembles the simulations, indicating 
that simulations are able to predict the amount of bias introduced when performing dual-
tracer imaging. 
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Figure 5-7  Estimating the bias encountered when performing dual-tracer imaging. Plots in red represent tumour tissue and 
plots in green represent normal tissue. Plots are shown in groups of four for each of the potential injection delays being 
investigated. The left plot for each colour represents bias calculated from simulations and the right plot reflects real data. 
It can be seen that bias determined from simulations closely resembles bias calculated from real pre-clinical data. 
 
By selection of the appropriate injection delay the error can be minimised as far as 
necessary within the bounds imposed by logistics. In all experiments, the error is non-zero 
and both bias and the increase in parameter variance must be mitigated against the 
logistics of the scanning protocol. Figure 5-8 shows the distribution of estimated VT values 
for both normal (green) and tumour (red) tissue and compares this to the estimates 
obtained from the single-tracer VT (within blue box) over the ROI for the same volumes in 
the single-tracer case. Both Figure 5-7 and Figure 5-8 show that with an injection delay of 
20 minutes the additional bias and variance induced by dual-tracer imaging become difficult 
to discern, especially for Tracer 1. 
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Figure 5-8  Explicitly showing the bias in VT when performing dual-tracer imaging. Plots in red represent tumour tissue and 
plots in green represent normal tissue. Plots in the blue box represent single-tracer VT distributions calculated from real 
single-tracer data. The remaining plots represent VT calculated from dual-tracer simulations. It can be seen that for injection 
delays of 20 and 30 minutes, the distribution of VT for both tumour and normal tissue very closely reflect the distributions 
for single-tracer imaging for both tracers, with errors slightly higher for the second tracer.  
Real dual-tracer experiments 
Figure 5-9 and Figure 5-10 show the results of the actual dual-tracer experiment, where a 
dynamic 18F-FDOPA image followed immediately by a dynamic 18F-FDG image was 
acquired in a NOD/SCID mouse bearing a patient derived (WK1) xenograft in the right 
striatum. Here, an injection delay of 20 minutes was selected, as this appeared to be a 
conservative choice based on results from simulations above. Figure 5-9 shows a coronal 
slice of the mouse illustrating the uptake of the tracers and the calculated macroscopic 
parameters VT and KI. A corresponding contrast enhanced MRI is shown in a) for anatomic 
reference. 18F-FDOPA and 18F-FDG uptake is shown in b) and e) respectively, with the 
dual-tracer volume shown in d). The tumour is clearly identifiable, as is the excess cortical 
uptake of FDG, common to this tracer. The calculated kinetic parameter for each tracer is 
shown in c) and f). It can be seen that the values are higher in tumour tissue for both tracers. 
It is also higher in the cortical 18F-FDG tissue than 18F-FDOPA, most likely due to the higher 
cortical uptake of 18F-FDG, which can be seen in c).  
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For comparison, kinetic parameters for the tumour and cortical tissue were obtained from 
real single-tracer data (for 18F-FDOPA; previous experimental data) and the literature 
(130, 131) (for 18F-FDG) were obtained and used for comparison against the real dual-
tracer data. Figure 5-10 shows a comparison of the calculated volume of distributions for 
both brain tumour and normal cortical tissue. The distribution of values for both tissues are 
comparable and are within one standard deviation of the mean predicted by the 
simulations.  
 
Figure 5-9  Uptake of 18F-FDOPA and 18F-FDG for tumour and normal tissue as measured using a truly combined 
NOD/SCID mouse data set. 2.75MBq of 18F-FDOPA was injected and 1.73MBq of 18F-FDG was injected. The MRI is shown 
in a) for anatomic reference. 18F-FDOPA and 18F-FDG uptake is shown in b) and e) respectively, with the dual-tracer 
volume shown in d). The tumour is clearly identifiable, as is the excess cortical uptake of 18F-FDG, common to this tracer. 
The calculated kinetic parameters for each tracer is shown in c) and f). It can be seen that these values are higher in 
tumour for both tracers. It is also higher in the cortical 18F-FDG tissue than 18F-FDOPA, most likely due to the higher cortical 
uptake of 18F-FDG, which can be seen in c).  
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Figure 5-10  Extracted dual-tracer VT and KI values for 18F-FDOPA and 18F-FDG compared to single-tracer (18F-FDOPA 
data from last experiment) and literature for 18F-FDG (130, 131). This shows values obtained while performing dual-tracer 
imaging are comparable to those found in the single-tracer scans and the literature, suggesting that dual-tracer imaging 
allows for recovery of important pharmacokinetic parameters.  
 
 
Discussion 
Positron emission tomography (PET) is increasingly used both pre-clinically and clinically 
due to its ability to provide detailed information on a single aspect of biological metabolism. 
However, individual counts from different tracers cannot be distinguished by PET scanners, 
and modelling is required to separate the individual signals when multiple PET tracers are 
used simultaneously. The alternative of performing individual scans on separate days may 
be impractical due to limitations on scanner and patient time, changes in tissue morphology 
and biology between scans and the reliance on successful image registration in deformable 
tissues.  
Several methods have been proposed to separate the signals from combined PET tracers, 
but all have drawbacks. Some approaches have required the fitting of pre-defined 
pharmacokinetic models to the combined data which limits their application to specific 
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biological cases. Other algorithms are used during image reconstruction, requiring data to 
be available in list-mode form and increasing the computational cost of the already 
expensive reconstruction methods. Algorithms eschewing kinetic models require the 
dynamics of the first tracer to have reached stability prior to injection of the second tracer, 
limiting the selection of tracers and injection intervals. This work proposed using the basis 
pursuit approach of (128), because it: 
 removes the need for a kinetic model to be provided a priori, allowing the data to 
determine the complexity of the tissue being analysed; 
 extends naturally to additional tracers that are simultaneously acquired; 
 is computationally efficient; 
 provides a global optimum; 
 can be performed post-reconstruction, i.e. without modification of the 
reconstruction algorithm; and 
 does not require a pre-defined model. 
This paper demonstrates the use of basis pursuit to separate tracers without the need to 
specify a model which allows much flexibility in the choice of radiotracer and which tissue 
is investigated. This provides a potentially more straight-forward way to separate signals 
both to test the feasibility of possible scanning protocols and subsequently in the actual 
study, and it must be stressed that although the method allows multiple potential protocols 
to be investigated, the study designer must decide if the selected protocol is viable. This 
study further demonstrates how simulations can be used to predict parameter error for a 
given injection delay by considering the reduction in signal fidelity caused by dual-tracer 
imaging independent of the residual due to noise (Figure 5-2). Using the proposed 
approach, researchers can optimise their imaging protocol prior to performing experiments 
to characterise the bias and increased variance caused by dual-tracer imaging. The ability 
to do this is critical, as in many cases, no ground truth is available to validate the results. 
Following a demonstration of separating dual-tracer curves using a controlled experiment, 
this difficulty is surmounted by showing the expected dual-tracer error on simulated dual-
tracer data, with extension to a real dual-tracer experiment, with extracted values 
concurring with single-tracer data. 
An experiment was performed using a physical phantom to demonstrate the dual-tracer 
methodology using real data while still retaining the original single-tracer signals. From this 
experiment it can be seen that provided care is taken to follow specific protocols, dual-
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tracer activity signals can be separated and the original single-tracer activities can be 
recovered with minimum loss. In addition, following the process outlined in Figure 5-2 
showed that values for KI as calculated from the dual-tracer compartment lie within 
expected values as calculated from simulations generated from curves measured in the 
single-tracer compartments. This suggests that the variance in kinetic parameters such as 
KI can be predicted using simulations prior to experiments being performed. 
Results from the simulations using the mouse data show the dual-tracer error reduces 
rapidly after the injection delay exceeds one minute, with greater errors occurring for the 
second tracer. This is most likely due to the residual activity from the first tracer contributing 
additional noise to the signal subsequent to injection of the second tracer. The separability 
of two tracers when performing dual-tracer imaging is affected by tissue biology, noise, 
relative injected activity and injection delay. For the specific cases used in this work, it 
appears that an injection delay of 10 to 20 minutes is sufficient to recover the kinetic 
parameters, which concurs with previous studies, with the work by Kadrmas et al (6) 
suggesting an injection delay of 10 minutes sufficient to separate signals for ATSM, PTSM 
and FDG. In addition, Ikoma et al (9) suggested an injection delay of 15 minutes sufficient 
to separate dual-tracer signals of Flumazenil followed by FDG. Finally, Koeppe et al (10) 
also showed correlating results, with their study suggesting an injection delay of 10-15 
minutes is sufficient to recover tracer signals from dual-tracer experiments of three 11C 
tracers. Therefore, this work adds to the growing body that dual-tracer signals can be 
recovered without a significant increase in scanning time. 
From the results of the actual dual-tracer experiment, shown in Figure 5-10, it can be seen 
that even with an injection delay of twenty minutes, VT and KI parameters recovered for 
each tracer within the tumour concurs closely with single-tracer imaging and the literature. 
The tumour uptake is enhanced relative to surrounding tissue in both tracers, apart from 
regions proximal to the cortical tissue where 18F-FDG uptake is also high (as is typical in 
the literature). The agreement between the recovered values of VT and KI with single-tracer 
comparisons within the tumour and the brain of the mouse suggests that kinetic parameters 
can be recovered within the bounds described by experimental simulation.  
The separability of two tracers when performing dual-tracer imaging is affected by tissue 
biology, noise, relative injected activity and injection delay. Tissue biology is not within the 
control of the experimenter, while ethical considerations limit the amount of activity that can 
be injected and limitations to scanner sensitivity, so some noise will always exist in the 
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data. However varying injection delays offers substantial latitude to devise a feasible 
experiment where information loss is negligible. 
Injection delay does require a trade-off as excessively short injection delays can 
substantially increase dual-tracer error, while long injection delays can unnecessarily 
lengthen scanning time. However, the results suggest that injection delays of 20-30 
minutes suffice in many pre-clinical cases. This will vary for different tracer pairs, but the 
evidence suggests that provided the injection of the second tracer occurs after the drop off 
of the initial spike, then the error appears to be manageable. Furthermore, injection delays 
can be shortened for tissues that rapidly metabolise the tracer or with more sensitive 
scanners. Tissues with slower dynamics may require a longer injection delay in order to be 
separated, because the long tails associated with slower dynamics can make tracers less 
distinguishable.  
Relative injected activity also affects the separability of the tracers: if the dose of the first 
tracer is too high in comparison to the second tracer, then the noise and residual dynamics 
from the first tracer will conceal the signal from the second tracer. Conversely, a higher 
injected dose for the second tracer will reduce the influence of the first tracer on this fit. 
However, increasing the tracer dose also increases the radiation exposure for the patients 
and thus will need to be considered carefully from an ethical perspective. In addition, 
inaccurate fits of the first tracer in tissues with slow dynamics may cause inaccuracies in 
fitting the second tracer. The selection of relative activity can be adapted to tissue of interest 
if its dynamics are known. 
A limitation of this work is that the injected doses were assumed to be the same in all 
experiments. Also, it is important to note that this work implicitly assumed the count-rate 
within the field of view is sufficiently controlled to avoid significant loss of sensitivity due to 
dead-time. Although doses are controlled within protocols to limit radiation exposure, 
significant dead-time losses cannot always be avoided, for instance when the initially 
unmixed bolus flows through the arteries in the field of view.  Hence future work will 
explicitly include this effect as an additional reduction in signal to noise ratio as a function 
of dose and to allow appropriate down-weighting of relevant frames to minimise resultant 
bias. A further limitation is that the effect of varying the tissue model complexity was not 
investigated. However, the main contribution of this chapter was to demonstrate the ability 
for a study designer to pre-validate a dual-tracer protocol. The limiting factor in any 
experiment will be the ability to recover original single-tracer signals from dual-tracer 
  
76 
images. An increase in the complexity of the pharmacokinetic model may have an effect 
on the recovered signals – however this can be determined on a case-by-case basis by the 
study designer. This allows the framework to exist in the general case, as adaption of the 
framework to different pathologies, organs and tracers will have an effect on the parameters 
required to allow dual-tracer imaging to be performed.  
This study has attempted to comprehensively demonstrate that it is possible to effectively 
predict dual-tracer error and use this to optimise the imaging protocols where dual-tracer 
imaging is used, by utilising the basis pursuit method proposed in (128). Although real data 
lacks a ground truth, it is possible to estimate the dual-tracer error from simulations and 
compare this to experiments. However, this method does assume that the study designer 
has some information on the expected dynamics of the tissues of interest. This study also 
assumes that a static noise parameter, c, is sufficient to estimate the bias when performing 
dual-tracer imaging. However, a spatially varying noise parameter may be more beneficial 
if scanning areas with varying susceptibility to noise. Even so, a static noise parameter may 
suffice in the majority of cases. Finally, this study assumes a correctly characterised blood 
activity concentration. Previous studies have investigated methods for determining the 
blood activity concentration (96, 132, 133) and this work assumes the study designer is 
capable of identifying the activity concentration effectively. 
Summary  
There are a large number of radioactive PET tracers that can be utilised to image a wide 
range of normal and pathological tissue. In this study the use of the basis pursuit method 
was utilised to separate two PET tracers that are scanned within the same imaging session. 
Basis pursuit extends naturally to dual-tracer imaging and avoids having to pre-define 
kinetic models for multiple combinations of tissue and tracer. Using this approach, the bias 
and variance can be established from simulations based on expected bounds of biology. 
Experiments show the predictions of the simulations correspond with results obtained in 
reality, allowing the injection delay to be selected appropriately to ensure additional error 
due to dual-tracer imaging is minimised. Based on this approach, the injection delay was 
selected for a true dual-tracer image. Dual-tracer imaging was performed, with uptake 
concurring with what would be expected of the cortical and tumour tissues. The VT was well 
within the bounds suggested by population data. As demonstrated by the concurrence of 
the results of the actual dual-tracer experiment and single-tracer data, dual-tracer imaging 
is practical in the experimental arena and possibly also the clinical arena. This work helps 
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to support the wider use of dual-tracer imaging and opens the door to a better 
understanding of those diseases such as brain cancer that are still relatively intractable for 
reasons that are poorly understood. 
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Chapter 6 Discussion 
PET imaging has the ability to provide information complementary to that obtained from 
MRI, improving both the diagnostic accuracy and treatment pathways for patients. Previous 
work has indicated that more than one biological factor may play a role in the development 
and progression of cancers such as glioma(134). For example, tracers such as 18F-FDOPA 
and 18F-FMISO identify two independent factors, namely tumour infiltration and tumour 
hypoxia, respectively. Obtaining information on two or more biological factors currently 
requires PET imaging to be performed on separate days, or at least far enough apart that 
residual activity from the first tracer does not contaminate the second. This approach is not 
practical in most clinical settings due to the significant increase in scanner and clinician 
time required.  
An alternative methodology to performing multiple PET scans is dual-tracer imaging, where 
two or more tracers are injected within the same imaging session. Since its conception by 
Huang in 1982, few studies have investigated the idea, and proposed techniques each 
suffer from particular limitations such as scanning from injection of the first tracer, imposing 
restrictions on tracer selection and requiring pre-defined kinetic models.  
Thesis Summary 
The contribution of this PhD was to devise a set of methodological tools to allow study 
designers to effectively implement an optimal dual-tracer imaging protocol in either the 
clinical or preclinical setting by allowing the continuous numerical relationship between 
protocol and additional noise to be understood. It also demonstrated how the dual-tracer 
problem could be investigated for any combination of tracers and biology without the need 
for explicitly specified compartment models by utilising the Basis Pursuit technique. The 
noise in a dual-tracer data set comprises of two components: The irreducible noise due to 
the scanner itself, and the noise added to the system when performing dual-tracer imaging. 
In the ideal case, this additional noise is zero. However, in the real-world case, this 
additional noise can be minimised by controlling the injection protocol.  
The first contribution of this PhD was to provide a technique to optimise static dual-tracer 
imaging protocols, specifically considering the case of glioma imaged with 18F-FDOPA and 
18F-FMISO, two tracers that identify biological processes that are thought to be important 
for glioma treatment. The benefit of using this particular tracer combination is that the 
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pharmacokinetic properties of 18F-FMISO allows for the assumption that the dynamics of 
this tracer are stable around two hours post injection, allowing for subtraction of the activity 
of this tracer using only a small number of frames imaged prior to the injection of 18F-
FDOPA. Using this framework, it was shown that two static images, one for each tracer, 
could be obtained with only a small increase in scanning time of about 5-10 minutes. Here, 
provided an 18F-FMISO stabilising time of at least 90 minutes is used, the additional noise 
encountered in the system does not exceed 10%. These findings show that subtracting the 
activity of one tracer from another can be achieved with little impact on image quality for 
either tracer. 
The second contribution of this PhD was to investigate a more complex version of the 
developed framework, where residual (but linear) dynamics remain for the first tracer. An 
example of this is the new tracer 64Cu-Epha2 coupled with 18F-FDOPA. As the uptake and 
excretion of 64Cu-EphA2 is very slow, it could be assumed that its dynamics were relatively 
linear and thus, for the second project, it was shown that linear interpolation could be used 
to estimate and remove this tracer from the 18F-FDOPA activity, provided that the 64Cu-
EphA2 imaging time was sufficient to characterise the linear interpolation parameters. For 
shorter 64Cu-EphA2 imaging times, performing linear interpolation offers no advantages. 
However, for 64Cu-EphA2 imaging times greater than 10 minutes, performing linear 
interpolation yields a 1-2% decrease in the resulting error.    With this contribution, it was 
shown that the previous framework could be extended to handle tracers with more complex 
(linear) dynamics, and that dual-tracer imaging has application outside of cancer diagnostic 
imaging, specifically the validation of new tracers.  
It became clear that dual-tracer imaging could be extended to other paradigms and that the 
field of dual-tracer imaging was incomplete without a general solution where residual 
dynamics from the first tracer exist. Therefore, the final contribution of the PhD was to 
devise a framework that provided a method for dual-tracer imaging to be performed 
regardless of the tissue imaged or the tracers used. Here, the well documented 
methodology of basis pursuit was extended into the dual-tracer paradigm and validated it 
using phantom and real mouse data. The framework can be used to pre-validate any 
imaging protocol considering any pair of tracers or biological scenarios for various injection 
times, provided dynamic information of both tracers is available. This work showed that, 
not only was dual-tracer imaging possible, but that the protocols can be pre-validated to 
assess validity prior to any experiments being performed. The benefit of basis pursuit is 
that there is no requirement for a kinetic model to be provided a priori, allowing the pre-
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validation technique to be extended to the general case of all tracers and all tissue biology 
types. This is important for cases where the tissue model is not known or not available, for 
example with new tracers or cases where more than one model exists in the field of view. 
This method allows the study designer to determine the feasibility of a scanning protocol 
using simulations prior to implementation, as the amount of error encountered can be 
estimated given the amount of scanner time available, the scanner being used, the tracers 
being injected and the tissue to be imaged.  
 
Study Limitations 
Like any study, there are limitations that need to be taken into consideration: 
Multi-tracer synthesis 
In order to perform real dual-tracer experiments, the experimenter needs to ensure that 
both radiotracers are synthesised and ready to be injected within a short period of time. 
This may pose a logistical challenge at sites where only one tracer is able to be generated 
at a time. However, for tracers with longer half-lives and higher yields, this is less of an 
issue. In this study we have shown in two instances that multi-tracer synthesis is possible, 
with the experiments performed in 64Cu-Epha2-18F-FDOPA and 18F-FDG -18F-FDOPA 
mice. 
Increased radiation dose 
With an additional injected PET tracer, comes an additional source of radiation exposure 
for the patient which will need to be taken into consideration in any ethics proposals made. 
This issue can be mitigated, however, as reductions in tracer doses can also be considered. 
With better attenuation correction and the advent of MR-PET, the CT scan may be 
obviated. 
Not all scenarios can be imaged with dual-tracer PET 
While the basis pursuit methodology and pre-validation framework can be applied to any 
pair of radiotracers, there are some scenarios where the pharmacokinetics of the tracers 
will not allow effective separation of the two signals. One such scenario is when the 
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dynamics of the two tracers are very slow but not static or linear. In addition, if the first 
tracer dynamics are very slow, the injection delay may be too significant to warrant dual-
tracer imaging. In this case, it may be beneficial to perform scans on separate days if 
possible. 
Training Data 
Pre-validating test radiotracers requires that a certain amount of information about the 
tracers is known a priori. For static scanning, tracer activity needs to be known. For dynamic 
imaging, pharmacokinetic parameters or a dynamic “training” image needs to be available. 
This may be difficult for novel radiotracers. 
Investigation of Model Complexity 
The experiments in this thesis rely on the model complexities of the test tracers used, such 
that time activity curves generated from pharmacokinetic parameters and curves 
investigated from real data are a direct reflection of the tracers investigated. Therefore, no 
experiments were performed investigating the effect of varying the tissue model complexity 
outside these compartmental models. More complex compartmental models may have an 
effect on the ability to separate tracer signals.  
Study sizes 
This thesis performs real-world experiments on multiple pre-clinical mouse subjects. 
However, the number of mouse subjects is small, allowing for inter-subject variability. 
However, the experiments performed in mouse subjects formed part of other projects, 
limiting the availability of more test subjects. In addition, the large number of intra-subject 
test voxels allows for comprehensive intra-subject voxel wise investigations to be 
performed.  
Future Research Paths 
Finally, this PhD opens up new research pathways and future topics of research that could 
expand on these presented techniques. One such pathway is expanding these dual-tracer 
techniques to the case of more than two injected tracers, and investigating the influence of 
noise and residual activities on the third injection. An investigation into the limit to the 
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number of tracers that can be injected in a scanning session would be of great interest in 
both the clinical and pre-clinical setting. 
Furthermore, with the development of PET/MR imaging systems, coupling dual-tracer PET 
imaging with modalities such as contrast enhanced MRI provides a means to directly 
compare biological functions with indices derived from BBB breakdown. For example, 
simultaneous imaging of 18F-FMISO, 18F-FDOPA, Contrast Enhanced MRI and Diffusion 
weighted imaging would allow simultaneous investigation into a wide range of biological 
and physiological processes of a tumour. 
Conclusions 
In summary, a general framework was devised that allows the effective implementation of 
dual-tracer PET imaging, providing study designers a toolkit for the separation of multiple 
tracers injected within a single scanning session. The first contribution devised a method 
for separation of two tracers when the dynamics of the first was stable at the injection of 
the tracer, with the specific case of treating glioma was considered. However, it became 
clear that dual-tracer imaging could be applied to other scenarios. Hence the second 
contribution investigated a pair of tracers where the first tracer activity could be assumed 
to be linear and was estimated from a few frames imaged prior to the injection of the second 
tracer. Finally, the dual-tracer framework was extended to the general case of any tissue 
and tracer combination by using a modified version of the basis pursuit method. 
The successful implementation of these methods brings the field of dual-tracer imaging 
closer towards pre-clinical and clinical translation. It substantially extends the versatility of 
dual-tracer imaging and gives rise to a new wave of information obtainable from PET 
imaging allowing researchers to gain greater insight into diseases that remain intractable 
such as advanced glioma. Finally, by utilising basis pursuit approaches, it is possible to 
consider any combination of tracers regardless of tracer and without devising specific 
model of uptake within tissue. 
 
  
  
83 
Bibliography 
1. Heiss WD, Raab P, Lanfermann H. Multimodality assessment of brain 
tumors and tumor recurrence. J Nucl Med. 2011;52(10):1585-600. 
2. Swanson KR, Alvord Jr EC, Murray JD. Virtual brain tumours (gliomas) 
enhance the reality of medical imaging and highlight inadequacies of 
current therapy. Br J Cancer. 2002;86(1):14-8. 
3. Bell C, Dowson N, Puttick S, Gal Y, Thomas P, Fay M, et al. Increasing 
feasibility and utility of (18)F-FDOPA PET for the management of glioma. 
Nucl Med Biol. 2015;42(10):788-95. 
4. Bell C, Dowson N, Fay M, Thomas P, Puttick S, Gal Y, et al. Hypoxia 
imaging in gliomas with 18F-fluoromisonidazole PET: toward clinical 
translation. Seminars in nuclear medicine. 2015;45(2):136-50. 
5. Huang SC, Carson RE, Hoffman EJ, Kuhl DE, Phelps ME. An investigation 
of a double-tracer technique for positron computerized tomography. J Nucl 
Med. 1982;23(9):816-22. 
6. Buckner JC. Factors influencing survival in high-grade gliomas. Semin 
Oncol. 2003;30(6 Suppl 19):10-4. 
7. Curran Jr WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach 
AJ, et al. Recursive partitioning analysis of prognostic factors in three 
Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer 
Inst. 1993;85(9):704-10. 
8. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344(2):114-23. 
9. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain 
tumours in adults. Lancet. 2003;361(9354):323-31. 
10. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, 
Cairncross JG, et al. Nomograms for predicting survival of patients with 
newly diagnosed glioblastoma: prognostic factor analysis of EORTC and 
NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008;9(1):29-38. 
11. Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, et al. 
Survival following surgery and prognostic factors for recently diagnosed 
malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 
2003;99(3):467-73. 
12. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et 
al. The 2007 WHO classification of tumours of the central nervous system. 
Acta Neuropathol. 2007;114(2):97-109. 
  
84 
13. Goodenberger ML, Jenkins RB. Genetics of adult glioma. Cancer 
genetics. 2012;205(12):613-21. 
14. Mamelak AN, Jacoby DB. Targeted delivery of antitumoral therapy to 
glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert 
opinion on drug delivery. 2007;4(2):175-86. 
15. Weber G. Enzymology of cancer cells (second of two parts). N Engl J 
Med. 1977;296(10):541-51. 
16. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head 
and neck cancer: changes during radiotherapy and impact on treatment 
outcome. Radiother Oncol. 1999;53(2):113-7. 
17. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz 
WH, et al. Oxygen distribution in squamous cell carcinoma metastases and 
its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 
1988;14(5):831-8. 
18. Kolstad P. Intercapillary distance, oxygen tension and local recurrence 
in cervix cancer. Scand J Clin Lab Invest Suppl. 1968;106:145-57. 
19. Folkman J. What is the evidence that tumors are angiogenesis 
dependent? J Natl Cancer Inst. 1990;82(1):4-6. 
20. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. 
Nat Rev Cancer. 2004;4(6):437-47. 
21. Hockel M, Vorndran B, Schlenger K, Baussmann E, Knapstein PG. 
Tumor oxygenation: a new predictive parameter in locally advanced cancer 
of the uterine cervix. Gynecol Oncol. 1993;51(2):141-9. 
22. Thomlinson RH, Gray LH. The histological structure of some human 
lung cancers and the possible implications for radiotherapy. Br J Cancer. 
1955;9(4):539-49. 
23. Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA, Workman P. 
Direct measurement of pO2 distribution and bioreductive enzymes in 
human malignant brain tumors. Int J Radiat Oncol Biol Phys. 
1994;29(3):427-31. 
24. Hall EJ. Radiobiology for the Radiologist. 4 ed. Philadelphia, PA: JB 
Lippincott Company; 1994. 
25. Menegakis A, Eicheler W, Yaromina A, Thames HD, Krause M, 
Baumann M. Residual DNA double strand breaks in perfused but not in 
unperfused areas determine different radiosensitivity of tumours. 
Radiother Oncol. 2011;100(1):137-44. 
  
85 
26. Helleday T, Lo J, van Gent DC, Engelward BP. DNA double-strand break 
repair: from mechanistic understanding to cancer treatment. DNA Repair 
(Amst). 2007;6(7):923-35. 
27. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-
stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol 
Chem. 1998;273(10):5858-68. 
28. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in 
human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. 
J Nucl Med. 1992;33(12):2133-7. 
29. Daumas-Duport C, Meder JF, Monsaingeon V, Missir O, Aubin ML, 
Szikla G. Cerebral gliomas: malignancy, limits and spatial configuration. 
Comparative data from serial stereotaxic biopsies and computed 
tomography (a preliminary study based on 50 cases). J Neuroradiol. 
1983;10(1):51-80. 
30. Scherer HJ. The forms of growth in gliomas and their practical 
significance. Brain. 1940;63:1-35. 
31. Chan JL, Lee SW, Fraass BA, Normolle DP, Greenberg HS, Junck LR, et 
al. Survival and failure patterns of high-grade gliomas after three-
dimensional conformal radiotherapy. J Clin Oncol. 2002;20(6):1635-42. 
32. Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 
2007;48(9):1468-81. 
33. Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, et al. 
18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG 
PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;47(6):904-11. 
34. Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, 
et al. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and 
tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med. 
2010;51(10):1532-8. 
35. Jora C, Mattakarottu JJ, Aniruddha PG, Mudalsha R, Singh DK, Pathak 
HC, et al. Comparative evaluation of 18F-FDOPA, 13N-AMMONIA, 18F-FDG 
PET/CT and MRI in primary brain tumors - A pilot study. Indian J Nucl Med. 
2011;26(2):78-81. 
36. Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, et al. 18F-
FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial 
experience. Eur J Radiol. 2009;71(2):242-8. 
37. Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, et 
al. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for 
  
86 
neurosurgical planning and radiotherapy target delineation: results of a 
prospective pilot study. Neuro Oncol. 2013;15(8):1058-67. 
38. Tripathi M, Sharma R, D'Souza M, Jaimini A, Panwar P, Varshney R, et 
al. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT 
for metabolic imaging of low grade gliomas. Clin Nucl Med. 
2009;34(12):878-83. 
39. Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, et al. 
Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing 
patients with brain tumors: the referring physician's perspective. J Nucl 
Med. 2012;53(3):393-8. 
40. Wahl L, Nahmias C. Modeling of fluorine-18-6-fluoro-L-Dopa in 
humans. J Nucl Med. 1996;37(3):432-7. 
41. Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K, 
et al. F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med. 
1996;37(7):1180-2. 
42. Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. 
Advanced MRI and PET imaging for assessment of treatment response in 
patients with gliomas. Lancet Neurol. 2010;9(9):906-20. 
43. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, 
Galanis E, et al. Updated response assessment criteria for high-grade 
gliomas: response assessment in neuro-oncology working group. J Clin 
Oncol. 2010;28(11):1963-72. 
44. Dunn IF, Heese O, Black PM. Growth factors in glioma angiogenesis: 
FGFs, PDGF, EGF, and TGFs. J Neurooncol. 2000;50(1-2):121-37. 
45. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D. Angiogenesis in 
gliomas: biology and molecular pathophysiology. Brain Pathol. 
2005;15(4):297-310. 
46. Spence AM, Muzi M, Swanson KR, O'Sullivan F, Rockhill JK, Rajendran 
JG, et al. Regional hypoxia in glioblastoma multiforme quantified with 
[18F]fluoromisonidazole positron emission tomography before 
radiotherapy: correlation with time to progression and survival. Clin Cancer 
Res. 2008;14(9):2623-30. 
47. Swanson KR, Chakraborty G, Wang CH, Rockne R, Harpold HL, Muzi M, 
et al. Complementary but distinct roles for MRI and 18F-fluoromisonidazole 
PET in the assessment of human glioblastomas. J Nucl Med. 2009;50(1):36-
44. 
  
87 
48. Szeto MD, Chakraborty G, Hadley J, Rockne R, Muzi M, Alvord Jr EC, et 
al. Quantitative metrics of net proliferation and invasion link biological 
aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in 
newly diagnosed glioblastomas. Cancer Res. 2009;69(10):4502-9. 
49. Kawai N, Maeda Y, Kudomi N, Miyake K, Okada M, Yamamoto Y, et al. 
Correlation of biological aggressiveness assessed by 11C-methionine PET 
and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly 
diagnosed glioblastoma. Eur J Nucl Med Mol Imaging. 2011;38(3):441-50. 
50. Karunanithi S, Sharma P, Kumar A, Khangembam BC, Bandopadhyaya 
GP, Kumar R, et al. Comparative diagnostic accuracy of contrast-enhanced 
MRI and (18)F-FDOPA PET-CT in recurrent glioma. Eur Radiol. 
2013;23(9):2628-35. 
51. Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J. Multivariate 
analysis of clinical prognostic factors in patients with glioblastoma 
multiforme treated with a combined modality approach. J Cancer Res Clin 
Oncol. 2003;129(8):477-84. 
52. Vos MJ, Hoekstra OS, Barkhof F, Berkhof J, Heimans JJ, van Groeningen 
CJ, et al. Thallium-201 single-photon emission computed tomography as an 
early predictor of outcome in recurrent glioma. J Clin Oncol. 
2003;21(19):3559-65. 
53. De Witte O, Levivier M, Violon P, Salmon I, Damhaut P, Wikler Jr D, et 
al. Prognostic value positron emission tomography with [18F]fluoro-2-
deoxy-D-glucose in the low-grade glioma. Neurosurgery. 1996;39(3):470-7. 
54. Santra A, Kumar R, Sharma P, Bal C, Julka PK, Malhotra A. F-18 FDG 
PET-CT for predicting survival in patients with recurrent glioma: a 
prospective study. Neuroradiology. 2011;53(12):1017-24. 
55. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. 
Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence 
of glioblastoma after irradiation in mice. J Clin Invest. 2010;120(3):694-705. 
56. Greenfield JP, Cobb WS, Lyden D. Resisting arrest: a switch from 
angiogenesis to vasculogenesis in recurrent malignant gliomas. J Clin Invest. 
2010;120(3):663-7. 
57. Mongiardi MP. Angiogenesis and hypoxia in glioblastoma: a focus on 
cancer stem cells. CNS Neurol Disord Drug Targets. 2012;11(7):878-83. 
58. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, et al. 
Tumor hypoxia has independent predictor impact only in patients with 
node-negative cervix cancer. J Clin Oncol. 2002;20(3):680-7. 
  
88 
59. Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, 
et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine 
cervix. Radiother Oncol. 1993;26(1):45-50. 
60. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. 
Association between tumor hypoxia and malignant progression in advanced 
cancer of the uterine cervix. Cancer Res. 1996;56(19):4509-15. 
61. Knocke TH, Weitmann HD, Feldmann HJ, Selzer E, Potter R. 
Intratumoral pO2-measurements as predictive assay in the treatment of 
carcinoma of the uterine cervix. Radiother Oncol. 1999;53(2):99-104. 
62. Sundfor K, Lyng H, Trope CG, Rofstad EK. Treatment outcome in 
advanced squamous cell carcinoma of the uterine cervix: relationships to 
pretreatment tumor oxygenation and vascularization. Radiother Oncol. 
2000;54(2):101-7. 
63. Cher LM, Murone C, Lawrentschuk N, Ramdave S, Papenfuss A, 
Hannah A, et al. Correlation of hypoxic cell fraction and angiogenesis with 
glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG 
PET, and immunohistochemical studies. J Nucl Med. 2006;47(3):410-8. 
64. Kawai N, Lin W, Cao WD, Ogawa D, Miyake K, Haba R, et al. Correlation 
between F-fluoromisonidazole PET and expression of HIF-1alpha and VEGF 
in newly diagnosed and recurrent malignant gliomas. Eur J Nucl Med Mol 
Imaging. 2014. 
65. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor 
hypoxia adversely affects the prognosis of carcinoma of the head and neck. 
Int J Radiat Oncol Biol Phys. 1997;38(2):285-9. 
66. Haensgen G, Krause U, Becker A, Stadler P, Lautenschlaeger C, 
Wohlrab W, et al. Tumor hypoxia, p53, and prognosis in cervical cancers. Int 
J Radiat Oncol Biol Phys. 2001;50(4):865-72. 
67. Nordsmark M, Overgaard J. A confirmatory prognostic study on 
oxygenation status and loco-regional control in advanced head and neck 
squamous cell carcinoma treated by radiation therapy. Radiother Oncol. 
2000;57(1):39-43. 
68. Rofstad EK, Sundfor K, Lyng H, Trope CG. Hypoxia-induced treatment 
failure in advanced squamous cell carcinoma of the uterine cervix is 
primarily due to hypoxia-induced radiation resistance rather than hypoxia-
induced metastasis. Br J Cancer. 2000;83(3):354-9. 
69. Rudat V, Vanselow B, Wollensack P, Bettscheider C, Osman-Ahmet S, 
Eble MJ, et al. Repeatability and prognostic impact of the pretreatment 
  
89 
pO(2) histography in patients with advanced head and neck cancer. 
Radiother Oncol. 2000;57(1):31-7. 
70. Wendt TG, Bank P. Prognostic factors in squamous cell carcinoma of 
the head and neck. Onkologie. 2002;25(3):208-12. 
71. Karunanithi S, Sharma P, Kumar A, Gupta DK, Khangembam BC, Ballal 
S, et al. Can F-FDOPA PET/CT predict survival in patients with suspected 
recurrent glioma? A prospective study. Eur J Radiol. 2013. 
72. Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, Nelson PT, et al. 
Hypoxia is important in the biology and aggression of human glial brain 
tumors. Clin Cancer Res. 2004;10(24):8177-84. 
73. Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, et al. 
Hypoxia-regulated protein expression, patient characteristics, and 
preoperative imaging as predictors of survival in adults with glioblastoma 
multiforme. Cancer. 2008;113(5):1032-42. 
74. Lally BE, Rockwell S, Fischer DB, Collingridge DR, Piepmeier JM, Knisely 
JP. The interactions of polarographic measurements of oxygen tension and 
histological grade in human glioma. Cancer J. 2006;12(6):461-6. 
75. Oliver L, Olivier C, Marhuenda FB, Campone M, Vallette FM. Hypoxia 
and the malignant glioma microenvironment: regulation and implications 
for therapy. Curr Mol Pharmacol. 2009;2(3):263-84. 
76. Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans 
L. [11C]methionine PET, histopathology, and survival in primary brain 
tumors and recurrence. AJNR Am J Neuroradiol. 2006;27(7):1432-7. 
77. Spetzler RF, Martin NA. A proposed grading system for arteriovenous 
malformations. J Neurosurg. 1986;65(4):476-83. 
78. Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H, et al. 
(1)(8)F-Fluoromisonidazole positron emission tomography may 
differentiate glioblastoma multiforme from less malignant gliomas. Eur J 
Nucl Med Mol Imaging. 2012;39(5):760-70. 
79. Yamamoto Y, Maeda Y, Kawai N, Kudomi N, Aga F, Ono Y, et al. Hypoxia 
assessed by 18F-fluoromisonidazole positron emission tomography in newly 
diagnosed gliomas. Nucl Med Commun. 2012;33(6):621-5. 
80. Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Assessment 
of hypoxia and perfusion in human brain tumors using PET with 18F-
fluoromisonidazole and 15O-H2O. J Nucl Med. 2004;45(11):1851-9. 
  
90 
81. Nioche C, Soret M, Gontier E, Lahutte M, Dutertre G, Dulou R, et al. 
Evaluation of quantitative criteria for glioma grading with static and 
dynamic 18F-FDopa PET/CT. Clin Nucl Med. 2013;38(2):81-7. 
82. Kratochwil C, Combs SE, Leotta K, Afshar-Oromieh A, Rieken S, Debus 
Jr, et al. Intra-individual comparison of 18F-FET and 18F-DOPA in PET 
imaging of recurrent brain tumors. Neuro-oncology. 2013(October):1-7. 
83. Kim B, Soisson E, Duma C, Chen P, Hafer R, Cox C, et al. Treatment of 
recurrent high grade gliomas with hypofractionated stereotactic image-
guided helical tomotherapy. Clin Neurol Neurosurg. 2011;113(6):509-12. 
84. Kadrmas DJ, Rust TC. Feasibility of rapid multitracer PET tumor 
imaging. Nuclear Science, IEEE Transactions on. 2005;52(5):1341-7. 
85. Figueiras FP, Jimnez X, Pareto D, G√≥mez V, Llop J, Herance R, et al. 
Simultaneous dual-tracer PET imaging of the rat brain and its application in 
the study of cerebral ischemia. Molecular imaging and biology : MIB : the 
official publication of the Academy of Molecular Imaging. 2011;13(3):500-
10. 
86. Verhaeghe J, Reader AJ. Simultaneous water activation and glucose 
metabolic rate imaging with PET. Physics in medicine and biology. 
2013;58(3):393-411. 
87. Ikoma Y, Toyama H, Uemura K, Uchiyama A, editors. Evaluation of the 
reliability in kinetic analysis for dual tracer injection of FDG and flumazenil 
PET study2001 2001. 
88. Koeppe RA, Raffel DM, Snyder SE, Ficaro EP, Kilbourn MR, Kuhl DE. 
Dual-[11C]tracer single-acquisition positron emission tomography studies. J 
Cereb Blood Flow Metab. 2001;21(12):1480-92. 
89. Kadrmas DJ, Rust TC, Hoffman JM. Single-scan dual-tracer FLT+FDG 
PET tumor characterization. Phys Med Biol. 2013;58(3):429-49. 
90. Zhang JL, Michael Morey A, Kadrmas DJ. Application of separable 
parameter space techniques to multi-tracer PET compartment modeling. 
Phys Med Biol. 2016;61(3):1238-58. 
91. Gao F, Liu H, Jian Y, Shi P. Dynamic dual-tracer PET reconstruction. Inf 
Process Med Imaging. 2009;21:38-49. 
92. Cheng X, Navab N, Ziegler S, Shi K. Direct Parametric Image 
Reconstruction of Rapid Multi-tracer PET. In: Mori K, Sakuma I, Sato Y, 
Barillot C, Navab N, editors. 8151: Springer Berlin Heidelberg; 2013. p. 155-
62. 
  
91 
93. Lage E, Parot V, Moore SC, Sitek A, Udias JM, Dave SR, et al. Recovery 
and normalization of triple coincidences in PET. Medical physics. 
2015;42(3):1398-410. 
94. Wang W, Lee NY, Georgi J-C, Narayanan M, Guillem J, Sch√∂der H, et 
al. Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic 
PET in head and neck cancer. Journal of nuclear medicine : official 
publication, Society of Nuclear Medicine. 2010;51(1):37-45. 
95. Huang SC, M.E P. Principle of Tracer Kinetic Modeling in Positron 
Emission Tomography and Autoradiography. New York: Raven Press; 1986. 
p. 287-345. 
96. Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang SC. 18F-FDOPA 
kinetics in brain tumors. J Nucl Med. 2007;48(10):1651-61. 
97. Huang SC, Barrio JR, Yu DC, Chen B, Grafton S, Melega WP, et al. 
Modelling approach for separating blood time-activity curves in positron 
emission tomographic studies. Phys Med Biol. 1991;36(6):749-61. 
98. Chondrogiannis S, Cristina Marzola M, Al-Nahhas A, Venkatanarayana 
TD, Mazza A, Opocher G, et al. Normal biodistribution pattern and 
physiologic variants of (18)F-DOPA PET imaging. Nuclear Medicine 
Communications. 2013;34(12):1141-9. 
99. Carlin S, Zhang H, Reese M, Ramos NN, Chen Q, Ricketts S-A. A 
Comparison of the Imaging Characteristics and Microregional Distribution 
of 4 Hypoxia PET Tracers. Journal of nuclear medicine : official publication, 
Society of Nuclear Medicine. 2014;55(3):515-21. 
100. Wang W, Georgi JC, Nehmeh SA, Narayanan M, Paulus T, Bal M, et al. 
Evaluation of a compartmental model for estimating tumor hypoxia via 
FMISO dynamic PET imaging. Phys Med Biol. 2009;54(10):3083-99. 
101. Eschmann S-M, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, 
et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in 
non-small cell lung cancer and head and neck cancer before radiotherapy. 
Journal of nuclear medicine : official publication, Society of Nuclear 
Medicine. 2005;46(2):253-60. 
102. Barrett HH, Wilson DW, Tsui BM. Noise properties of the EM 
algorithm: I. Theory. Physics in medicine and biology. 1994;39(5):833-46. 
103. Wilson DW, Tsui BM, Barrett HH. Noise properties of the EM 
algorithm: II. Monte Carlo simulations. Physics in medicine and biology. 
1994;39(5):847-71. 
  
92 
104. Chen K, Huang S-C, Yu D-C. The effects of measurement errors in the 
plasma radioactivity curve on parameter estimation in positron emission 
tomography. Physics in Medicine and Biology. 1991;36(9):1183-200. 
105. Logan J, Fowler JS, Volkow ND, Ding YS, Wang GJ, Alexoff DL. A strategy 
for removing the bias in the graphical analysis method. Journal of cerebral 
blood flow and metabolism : official journal of the International Society of 
Cerebral Blood Flow and Metabolism. 2001;21(3):307-20. 
106. Varga Jz, Szabo Z. Modified regression model for the Logan plot. 
Journal of cerebral blood flow and metabolism : official journal of the 
International Society of Cerebral Blood Flow and Metabolism. 
2002;22(2):240-4. 
107. Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, 
Conrad EU, et al. Hypoxia and glucose metabolism in malignant tumors: 
evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose 
positron emission tomography imaging. Clin Cancer Res. 2004;10(7):2245-
52. 
108. Thorwarth D, Eschmann SM, Paulsen F, Alber M. A kinetic model for 
dynamic [18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol. 
2005;50(10):2209-24. 
109. Corroyer-Dulmont A, Peres EA, Petit E, Durand L, Marteau L, Toutain 
J, et al. Noninvasive assessment of hypoxia with 3-[18F]-fluoro-1-(2-nitro-1-
imidazolyl)-2-propanol ([18F]-FMISO): a PET study in two experimental 
models of human glioma. Biol Chem. 2013;394(4):529-39. 
110. Dence CS, Ponde DE, Welch MJ, Lewis JS. Autoradiographic and small-
animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and 
the hypoxic selective (64)Cu-ATSM in a rodent model of cancer. Nucl Med 
Biol. 2008;35(6):713-20. 
111. Tochon-Danguy HJ, Sachinidis JI, Chan F, Chan JG, Hall C, Cher L, et al. 
Imaging and quantitation of the hypoxic cell fraction of viable tumor in an 
animal model of intracerebral high grade glioma using 
[18F]fluoromisonidazole (FMISO). Nucl Med Biol. 2002;29(2):191-7. 
112. Valable S, Petit E, Roussel S, Marteau L, Toutain J, Divoux D, et al. 
Complementary information from magnetic resonance imaging and (18)F-
fluoromisonidazole positron emission tomography in the assessment of the 
response to an antiangiogenic treatment in a rat brain tumor model. Nucl 
Med Biol. 2011;38(6):781-93. 
  
93 
113. Agostinelli S, Allison J, Amako K, Apostolakis J, Araujo H, Arce P, et al. 
Geant4‚ a simulation toolkit. Nuclear Instruments and Methods in Physics 
Research Section A: Accelerators, Spectrometers, Detectors and Associated 
Equipment. 2003;506(3):250-303. 
114. Allison J, Amako K, Apostolakis J, Araujo H, Dubois PA, Asai M, et al. 
Geant4 developments and applications. Nuclear Science, IEEE Transactions 
on. 2006;53(1):270-8. 
115. Siemens-AG. Technical Document “microPET List Mode format”. 
2006. 
116. Puttick S, Stringer BW, Day BW, Bruce ZC, Ensbey KS, Mardon K, et al. 
EphA2 as a Diagnostic Imaging Target in Glioblastoma: A Positron Emission 
Tomography/Magnetic Resonance Imaging Study. Molecular imaging. 
2015;14:385-99. 
117. Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, et 
al. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. 
Neoplasia. 2005;7(8):717-22. 
118. Wen PY, Kesari S. Malignant gliomas. Curr Neurol Neurosci Rep. 
2004;4(3):218-27. 
119. Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel 
molecular marker and target in glioblastoma multiforme. Mol Cancer Res. 
2005;3(10):541-51. 
120. Liu F, Park PJ, Lai W, Maher E, Chakravarti A, Durso L, et al. A genome-
wide screen reveals functional gene clusters in the cancer genome and 
identifies EphA2 as a mitogen in glioblastoma. Cancer Res. 
2006;66(22):10815-23. 
121. Wang LF, Fokas E, Bieker M, Rose F, Rexin P, Zhu Y, et al. Increased 
expression of EphA2 correlates with adverse outcome in primary and 
recurrent glioblastoma multiforme patients. Oncol Rep. 2008;19(1):151-6. 
122. Goldenberg DM. Targeted therapy of cancer with radiolabeled 
antibodies. J Nucl Med. 2002;43(5):693-713. 
123. Goldenberg DM. Advancing role of radiolabeled antibodies in the 
therapy of cancer. Cancer Immunol Immunother. 2003;52(5):281-96. 
124. Goldenberg DM, Sharkey RM. Advances in cancer therapy with 
radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging. 
2006;50(4):248-64. 
125. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 
2013;341(6151):1192-8. 
  
94 
126. Mould DR, Sweeney KR. The pharmacokinetics and 
pharmacodynamics of monoclonal antibodies--mechanistic modeling 
applied to drug development. Curr Opin Drug Discov Devel. 2007;10(1):84-
96. 
127. Rivest-Hénault D, Dowson N, Greer P, J. F, J. D. Robust inverse-
consistent affine registration for the construction of CT-MR atlases of pelvis 
for the guidance of prostate radiation therapy. Medical Image Analysis. 
2014;Under Review. 
128. Gunn RN, Gunn SR, Turkheimer FE, Aston JA, Cunningham VJ. Positron 
emission tomography compartmental models: a basis pursuit strategy for 
kinetic modeling. J Cereb Blood Flow Metab. 2002;22(12):1425-39. 
129. Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography 
compartmental models. J Cereb Blood Flow Metab. 2001;21(6):635-52. 
130. Alf MF, Wyss MT, Buck A, Weber B, Schibli R, Kramer SD. 
Quantification of brain glucose metabolism by 18F-FDG PET with real-time 
arterial and image-derived input function in mice. J Nucl Med. 
2013;54(1):132-8. 
131. Bolcaen J, Lybaert K, Moerman L, Descamps B, Deblaere K, Boterberg 
T, et al. Kinetic Modeling and Graphical Analysis of 18F-Fluoromethylcholine 
(FCho), 18F-Fluoroethyltyrosine (FET) and 18F-Fluorodeoxyglucose (FDG) 
PET for the Fiscrimination between High-Grade Glioma and Radiation 
Necrosis in Rats. PLoS ONE. 2016;11(8). 
132. Tantawy MN, Peterson TE. Simplified [(18)F]FDG Image-Derived Input 
Function Using the Left Ventricle, Liver, and One Venous Blood Sample. 
Molecular imaging. 2010;9(2):76-86. 
133. Zhou S, Chen K, Reiman EM, Li D-m, Shan B. A method of generating 
image derived input function in quantitative (18)F-FDG PET study based on 
the monotonicity of the input and output function curve. Nuclear medicine 
communications. 2012;33(4):10.1097/MNM.0b013e32834f262e. 
134. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 
2000;100(1):57-70. 
 
